STOCK TITAN

Greenland Mines' nine-month loss widens to $31.2M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Greenland Mines Ltd (GRML) reported a net loss of $31,184,340 for the nine months ended September 30, 2026, compared with $8,773,996 in 2025. Net cash used in operating activities was $22,230,519, versus $4,610,390. At September 30, cash and equivalents were $57,393,437.

The company completed acquisitions of the Skaergaard and Sarfartoq exploration projects in Greenland. At September 30, their mineral rights and exploration licenses had carrying values of $48,416,474 and $25,438,830, respectively. The projects are at an early exploration stage, have no established mineral reserves and have generated no revenue. The company also recognized a $2,045,253 noncash impairment of generic-drug licenses after its strategic pivot.

Management concluded that cash and its spending forecast, assuming no additional financing, were sufficient for planned operations for at least 12 months from issuance; it expects to need additional capital over the longer term to advance its mineral properties.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss was $31,184,340, versus $8,773,996 in 2025.
  • Moderate pointNine-month operating cash use was $22,230,519, versus $4,610,390 in 2025.

Filing Explained

At September 30, 2026, up to 40,800,776 approved Series C conversion shares remained unissued, so their potential ownership dilution had not yet taken effect.

The 10-Q reports Greenland Mines had 14,819,209 common shares outstanding on November 12, 2026; stockholders approved issuance of up to 40,800,776 common shares upon conversion of Series C preferred stock, but that conversion had not occurred by September 30, 2026. If converted, those additional common shares would reduce existing holders’ percentage ownership, absent offsetting changes.

Conversion is blocked until the earlier of January 8, 2027 or the next trading day after five consecutive Nasdaq closes at or above $15.00 per share; neither condition had been met by September 30, 2026. At September 30, the company reported 13,685,941 common shares outstanding, alongside the approved conversion ceiling of 40,800,776 shares.

The completed Sarfartoq acquisition included issuance of 1,040,676 common shares and 359,324 Series R preferred shares; Series R was non-voting and not convertible without stockholder approval as of September 30, 2026. The filing presents share data retroactively for the August 24, 2026 1-for-50 reverse split, which left 1,000,000,000 common shares authorized.

Nine-month net loss $31,184,340 Nine months ended September 30, 2026; $8,773,996 for the same period in 2025
Net cash used in operating activities $22,230,519 Nine months ended September 30, 2026; $4,610,390 for the same period in 2025
Cash and cash equivalents $57,393,437 As of September 30, 2026
Net cash provided by financing activities $93,370,984 Nine months ended September 30, 2026
Impairment expense $2,045,253 Recognized in the nine months ended September 30, 2026 for generic-drug licenses
Skaergaard mineral rights and exploration licenses $48,416,474 Carrying value as of September 30, 2026
Sarfartoq mineral rights and exploration license $25,438,830 Carrying value as of September 30, 2026
Indicated Mineral Resources technical
"estimated Indicated Mineral Resources of 153.6 million tons"
Indicated mineral resources are quantities and qualities of a mineral deposit estimated with a reasonable level of confidence based on spaced sampling and analysis, sitting between a rough guess and a high-certainty measurement. For investors, they matter because they support preliminary economic studies and mine planning—think of them as a reasonably reliable shopping list for a recipe, useful for deciding whether to invest further but not yet proof that profitable extraction is guaranteed.
Inferred Mineral Resources technical
"Inferred Mineral Resources of 177.5 million tons"
An inferred mineral resource is an estimate of the quantity and grade of minerals in the ground based on limited sampling and geological information, where confidence is low and continuity is uncertain. For investors it signals potential value but also higher risk—like a rough sketch of a hidden treasure that requires much more exploration and testing before you can reliably judge its size or economic worth.
asset acquisition financial
"accounted for as an asset acquisition under ASC 805-50"
An asset acquisition is when a company buys specific pieces of another business—such as equipment, buildings, patents, customer lists, or inventory—rather than buying the other company’s stock. For investors, it matters because this lets a buyer add value or cut costs without taking on unwanted liabilities, similar to shopping for and installing only the useful appliances in a house instead of buying the whole property; the move can change future revenue, costs and risk.
measurement alternative financial
"elected to measure the investment using the measurement alternative"
beneficial ownership limitation financial
"subject to a beneficial ownership limitation of 4.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
non-binding offtake agreement technical
"entered into a non-binding offtake agreement with Neo Performance Materials"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash did GRML pay for the Sarfartoq acquisition?

GRML paid $19,882,065 in cash and issued 1,040,676 common shares and 359,324 Series R Convertible Preferred Stock shares at closing.

When can GRML's Series C preferred shares convert?

Conversion is restricted until the earlier of January 8, 2027, or the next trading day after the fifth consecutive trading day on which the Nasdaq closing price is at least $15.00 per share. Neither condition had been met as of September 30, 2026, and conversion had not occurred.

Does GRML have a binding buyer for Sarfartoq production?

No binding purchase commitment is in place. The non-binding agreement with related party Neo Performance Materials would give it the right to purchase up to 60% of future production, but neither party is obligated to buy or sell, and no amounts had been recorded under the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
falseQ320260001907223--12-310.020.020.020.020.020.020.020.50.020.016670.020.0210.50.5xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:puregrml:segmentgrml:projectutr:Tutr:ggrml:licenseiso4217:CADiso4217:EURgrml:drug_licensegrml:loangrml:instrumentgrml:investorgrml:offeringiso4217:CADxbrli:shares00019072232026-01-012026-09-300001907223us-gaap:CommonStockMember2026-01-012026-09-300001907223us-gaap:WarrantMember2026-01-012026-09-3000019072232026-11-1200019072232026-09-3000019072232025-12-3100019072232026-08-242026-08-2400019072232026-07-012026-09-3000019072232025-07-012025-09-3000019072232025-01-012025-09-300001907223us-gaap:CommonStockMember2024-12-310001907223us-gaap:PreferredStockMember2024-12-310001907223us-gaap:AdditionalPaidInCapitalMember2024-12-310001907223grml:CommonStockToBeIssuedMember2024-12-310001907223us-gaap:RetainedEarningsMember2024-12-3100019072232024-12-310001907223us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100019072232025-01-012025-03-310001907223us-gaap:CommonStockMember2025-01-012025-03-310001907223us-gaap:RetainedEarningsMember2025-01-012025-03-310001907223us-gaap:CommonStockMember2025-03-310001907223us-gaap:PreferredStockMember2025-03-310001907223us-gaap:AdditionalPaidInCapitalMember2025-03-310001907223grml:CommonStockToBeIssuedMember2025-03-310001907223us-gaap:RetainedEarningsMember2025-03-3100019072232025-03-310001907223us-gaap:CommonStockMember2025-04-012025-06-300001907223us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-3000019072232025-04-012025-06-300001907223grml:NoteConversionMemberus-gaap:CommonStockMember2025-04-012025-06-300001907223grml:NoteConversionMemberus-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001907223grml:NoteConversionMember2025-04-012025-06-300001907223grml:WarrantsExerciseMemberus-gaap:CommonStockMember2025-04-012025-06-300001907223grml:WarrantsExerciseMemberus-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001907223grml:WarrantsExerciseMember2025-04-012025-06-300001907223grml:CommonStockStockSubscriptionsMemberus-gaap:CommonStockMember2025-04-012025-06-300001907223grml:CommonStockStockSubscriptionsMemberus-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001907223grml:CommonStockStockSubscriptionsMember2025-04-012025-06-300001907223grml:PreferredBStockIssuedMemberus-gaap:PreferredStockMember2025-04-012025-06-300001907223grml:PreferredBStockIssuedMemberus-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001907223grml:PreferredBStockIssuedMember2025-04-012025-06-300001907223us-gaap:RetainedEarningsMember2025-04-012025-06-300001907223us-gaap:CommonStockMember2025-06-300001907223us-gaap:PreferredStockMember2025-06-300001907223us-gaap:AdditionalPaidInCapitalMember2025-06-300001907223grml:CommonStockToBeIssuedMember2025-06-300001907223us-gaap:RetainedEarningsMember2025-06-3000019072232025-06-300001907223us-gaap:CommonStockMember2025-07-012025-09-300001907223us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001907223us-gaap:PreferredStockMember2025-07-012025-09-300001907223grml:ForwardSharePurchaseAgreementMemberus-gaap:CommonStockMember2025-07-012025-09-300001907223grml:ForwardSharePurchaseAgreementMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001907223grml:ForwardSharePurchaseAgreementMember2025-07-012025-09-300001907223grml:AtTheMarketSalesAgreementMemberus-gaap:CommonStockMember2025-07-012025-09-300001907223grml:AtTheMarketSalesAgreementMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001907223grml:AtTheMarketSalesAgreementMember2025-07-012025-09-300001907223us-gaap:RetainedEarningsMember2025-07-012025-09-300001907223us-gaap:CommonStockMember2025-09-300001907223us-gaap:PreferredStockMember2025-09-300001907223us-gaap:AdditionalPaidInCapitalMember2025-09-300001907223grml:CommonStockToBeIssuedMember2025-09-300001907223us-gaap:RetainedEarningsMember2025-09-3000019072232025-09-300001907223us-gaap:CommonStockMember2025-12-310001907223us-gaap:PreferredStockMember2025-12-310001907223us-gaap:AdditionalPaidInCapitalMember2025-12-310001907223grml:CommonStockToBeIssuedMember2025-12-310001907223us-gaap:RetainedEarningsMember2025-12-310001907223us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:CommonStockMember2026-01-012026-03-310001907223us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001907223us-gaap:ShareBasedPaymentArrangementEmployeeMember2026-01-012026-03-310001907223us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2026-01-012026-03-310001907223us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001907223us-gaap:ShareBasedPaymentArrangementNonemployeeMembergrml:CommonStockToBeIssuedMember2026-01-012026-03-310001907223us-gaap:ShareBasedPaymentArrangementNonemployeeMember2026-01-012026-03-310001907223us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-3100019072232026-01-012026-03-310001907223us-gaap:PreferredStockMember2026-01-012026-03-310001907223us-gaap:CommonStockMember2026-01-012026-03-310001907223us-gaap:RetainedEarningsMember2026-01-012026-03-310001907223us-gaap:CommonStockMember2026-03-310001907223us-gaap:PreferredStockMember2026-03-310001907223us-gaap:AdditionalPaidInCapitalMember2026-03-310001907223grml:CommonStockToBeIssuedMember2026-03-310001907223us-gaap:RetainedEarningsMember2026-03-3100019072232026-03-310001907223us-gaap:CommonStockMember2026-04-012026-06-300001907223us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-3000019072232026-04-012026-06-300001907223us-gaap:RetainedEarningsMember2026-04-012026-06-300001907223us-gaap:CommonStockMember2026-06-300001907223us-gaap:PreferredStockMember2026-06-300001907223us-gaap:AdditionalPaidInCapitalMember2026-06-300001907223grml:CommonStockToBeIssuedMember2026-06-300001907223us-gaap:RetainedEarningsMember2026-06-3000019072232026-06-300001907223us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001907223us-gaap:ShareBasedPaymentArrangementEmployeeMember2026-07-012026-09-300001907223us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001907223us-gaap:ShareBasedPaymentArrangementNonemployeeMember2026-07-012026-09-300001907223us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001907223us-gaap:CommonStockMember2026-07-012026-09-300001907223us-gaap:PreferredStockMember2026-07-012026-09-300001907223us-gaap:RetainedEarningsMember2026-07-012026-09-300001907223us-gaap:CommonStockMember2026-09-300001907223us-gaap:PreferredStockMember2026-09-300001907223us-gaap:AdditionalPaidInCapitalMember2026-09-300001907223grml:CommonStockToBeIssuedMember2026-09-300001907223us-gaap:RetainedEarningsMember2026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2026-01-012026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2025-01-012025-09-300001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2026-01-012026-09-300001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2025-01-012025-09-3000019072232026-03-012026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2026-07-032026-07-030001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2026-07-312026-07-310001907223grml:ShareBasedCompensationExpenseMember2025-07-012025-09-300001907223grml:ShareBasedCompensationExpenseMember2025-01-012025-09-300001907223grml:ShareBasedCompensationExpenseIncludedInGeneralAndAdministrativeExpensesMember2025-07-012025-09-300001907223grml:ShareBasedCompensationExpenseIncludedInGeneralAndAdministrativeExpensesMember2025-01-012025-09-300001907223grml:ShareBasedCompensationExpenseIncludedInResearchAndDevelopmentExpensesMember2025-07-012025-09-300001907223grml:ShareBasedCompensationExpenseIncludedInResearchAndDevelopmentExpensesMember2025-01-012025-09-300001907223us-gaap:FairValueInputsLevel1Member2026-09-300001907223us-gaap:FairValueInputsLevel2Member2026-09-300001907223us-gaap:FairValueInputsLevel3Member2026-09-300001907223us-gaap:FairValueInputsLevel1Member2025-12-310001907223us-gaap:FairValueInputsLevel2Member2025-12-310001907223us-gaap:FairValueInputsLevel3Member2025-12-310001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2026-06-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-06-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2026-07-012026-09-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-07-012025-09-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2026-09-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-09-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-12-310001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-12-310001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2026-01-012026-09-300001907223us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2025-01-012025-09-300001907223us-gaap:MeasurementInputRiskFreeInterestRateMember2026-06-300001907223us-gaap:MeasurementInputExpectedDividendRateMember2026-06-300001907223us-gaap:MeasurementInputOptionVolatilityMember2026-06-300001907223us-gaap:MeasurementInputExpectedTermMember2026-06-300001907223grml:PrivatePlacementWarrantsMember2026-09-2200019072232026-09-220001907223grml:LegacyPrivateWarrantsMember2026-09-300001907223us-gaap:WarrantMember2026-09-300001907223us-gaap:WarrantMember2026-07-012026-09-300001907223us-gaap:WarrantMember2026-01-012026-09-3000019072232026-03-042026-09-300001907223us-gaap:BuildingAndBuildingImprovementsMember2026-09-300001907223srt:MinimumMembergrml:AccommodationAndOperationalContainersMember2026-09-300001907223srt:MaximumMembergrml:AccommodationAndOperationalContainersMember2026-09-300001907223us-gaap:TransportationEquipmentMember2026-09-300001907223grml:DrillingLaboratorySurveyAndGeophysicalEquipmentMember2026-09-300001907223us-gaap:TechnologyEquipmentMember2026-09-300001907223us-gaap:OtherMachineryAndEquipmentMember2026-09-300001907223us-gaap:BuildingAndBuildingImprovementsMember2025-12-310001907223grml:DrillingLaboratorySurveyAndGeophysicalEquipmentMember2025-12-310001907223us-gaap:TransportationEquipmentMember2025-12-310001907223us-gaap:WarrantMember2026-01-012026-09-300001907223us-gaap:WarrantMember2025-01-012025-09-300001907223us-gaap:SeriesCPreferredStockMember2026-01-012026-09-300001907223us-gaap:SeriesCPreferredStockMember2025-01-012025-09-300001907223grml:SeriesRConvertiblePreferredStockMember2026-01-012026-09-300001907223grml:SeriesRConvertiblePreferredStockMember2025-01-012025-09-300001907223us-gaap:SeriesCPreferredStockMember2026-09-3000019072232026-09-030001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Membergrml:SeriesRConvertiblePreferredStockMember2026-09-012026-09-010001907223grml:SeriesRConvertiblePreferredStockMember2026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2026-03-042026-03-040001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2026-03-040001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Membergrml:MineralRightsAndExplorationLicensesMember2026-03-040001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Membergrml:MineralRightsAndExplorationLicensesMember2026-03-042026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Membergrml:MineralRightsAndExplorationLicensesMember2026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Member2026-03-042026-09-300001907223grml:SkaergaardAcquisitionOfGreenlandMinesCorp.Membergrml:MineralRightsAndExplorationLicensesMember2026-03-042026-03-040001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Memberus-gaap:CommonStockMember2026-09-012026-09-010001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2026-09-012026-09-010001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2026-09-010001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Membergrml:MineralRightsAndExplorationLicensesMember2026-09-010001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Membergrml:MineralRightsAndExplorationLicensesMember2026-09-012026-09-300001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Membergrml:MineralRightsAndExplorationLicensesMember2026-09-300001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2026-09-012026-09-300001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Member2026-09-300001907223grml:NonExclusiveLicenseAgreementMember2026-09-300001907223grml:NonExclusiveLicenseAgreementMember2025-12-310001907223grml:VariousGenericDrugsMember2026-09-300001907223grml:VariousGenericDrugsMember2025-12-310001907223grml:FourGenericDrugsEncoreMember2026-09-300001907223grml:FourGenericDrugsEncoreMember2025-12-310001907223grml:NeedlelessSyringeLicenseMember2026-09-300001907223grml:NeedlelessSyringeLicenseMember2025-12-310001907223us-gaap:PatentsMember2026-09-300001907223us-gaap:PatentsMember2025-12-310001907223grml:MineralRightsAndExplorationLicensesSkaergaardMember2026-09-300001907223grml:MineralRightsAndExplorationLicensesSkaergaardMember2025-12-310001907223grml:MineralRightsAndExplorationLicensesSarfartoqMember2026-09-300001907223grml:MineralRightsAndExplorationLicensesSarfartoqMember2025-12-310001907223grml:NonExclusiveLicenseAgreementMember2023-03-052023-03-050001907223grml:VariousGenericDrugsMember2015-01-012015-12-310001907223grml:VariousGenericDrugsMember2026-03-310001907223grml:VariousGenericDrugsMember2026-07-012026-09-300001907223grml:FourGenericDrugsEncoreMember2022-09-122022-09-120001907223grml:FourGenericDrugsEncoreMember2026-03-310001907223grml:FourGenericDrugsEncoreMember2026-07-012026-09-300001907223grml:NeedlelessSyringeLicenseMember2023-12-012023-12-010001907223us-gaap:PatentsMember2026-01-012026-09-300001907223grml:ExclusiveWorldwideLicenseAgreementMember2022-12-152022-12-150001907223grml:ExclusiveWorldwideLicenseAgreementMember2026-09-300001907223grml:ExclusiveWorldwideLicenseAgreementMember2025-12-310001907223grml:MineralRightsAndExplorationLicensesSkaergaardMember2026-01-012026-09-300001907223grml:AnorTechIncMember2026-06-2200019072232026-06-222026-06-220001907223grml:AnorTechIncMember2026-06-222026-06-220001907223grml:AnorTechIncMember2026-06-2200019072232026-06-220001907223us-gaap:ConvertibleDebtMembergrml:AustriaCapitalLLCMembergrml:AustriaCapitalLLCConvertiblePromissoryNoteMember2024-12-040001907223us-gaap:ConvertibleDebtMembergrml:AustriaCapitalLLCMembergrml:AustriaCapitalLLCConvertiblePromissoryNoteMember2024-12-042024-12-040001907223grml:AustriaCapitalLLCMembergrml:AustriaCapitalLLCConvertiblePromissoryNoteMember2024-12-040001907223grml:AustriaCapitalLLCMember2024-12-042024-12-040001907223grml:AustriaCapitalLLCMemberus-gaap:CommonStockMember2024-12-040001907223us-gaap:LoansPayableMembergrml:RedRoadHoldingsPromissoryNoteMember2024-12-012025-04-300001907223us-gaap:LoansPayableMembergrml:RedRoadHoldingsPromissoryNoteMember2025-04-300001907223us-gaap:ConvertibleDebtMembergrml:A3iLPInstitutionalInvestorSecuritiesPurchaseAgreementMember2025-01-232025-01-230001907223us-gaap:ConvertibleDebtMembergrml:A3iLPInstitutionalInvestorSecuritiesPurchaseAgreementMember2025-01-230001907223us-gaap:ConvertibleDebtMember2025-01-232025-01-230001907223us-gaap:ConvertibleDebtMember2025-01-230001907223grml:A3iLPInstitutionalInvestorSecuritiesPurchaseAgreementMember2025-01-012025-09-300001907223grml:A3iLPInstitutionalInvestorSecuritiesPurchaseAgreementMember2026-01-012026-09-300001907223grml:A3iLPInstitutionalInvestorSecuritiesPurchaseAgreementMember2026-07-012026-09-300001907223srt:ChiefExecutiveOfficerMemberus-gaap:RelatedPartyMember2024-10-242024-10-240001907223srt:ChiefExecutiveOfficerMemberus-gaap:RelatedPartyMember2024-10-240001907223srt:ChiefFinancialOfficerMemberus-gaap:RelatedPartyMember2024-08-152024-08-150001907223srt:ChiefFinancialOfficerMemberus-gaap:RelatedPartyMember2024-08-150001907223grml:FirstAnniversaryMembersrt:ChiefFinancialOfficerMemberus-gaap:RelatedPartyMember2024-08-152024-08-150001907223grml:SecondAnniversaryMembersrt:ChiefFinancialOfficerMemberus-gaap:RelatedPartyMember2024-08-152024-08-150001907223us-gaap:RelatedPartyMember2026-03-040001907223us-gaap:RelatedPartyMember2026-03-042026-03-040001907223us-gaap:RelatedPartyMember2026-09-300001907223us-gaap:RelatedPartyMember2026-07-012026-09-300001907223us-gaap:RelatedPartyMember2026-01-012026-09-300001907223srt:ChiefExecutiveOfficerMember2026-05-142026-05-140001907223srt:ChiefExecutiveOfficerMember2026-06-302026-06-300001907223srt:ChiefExecutiveOfficerMember2026-04-012026-06-300001907223grml:OfftakeAgreementMemberus-gaap:RelatedPartyMember2026-09-012026-09-010001907223grml:EquityIncentivePlanMember2026-01-012026-09-300001907223grml:EquityIncentivePlanMember2025-01-012025-12-310001907223grml:EquityIncentivePlanMembersrt:ManagementMember2025-01-012025-12-310001907223grml:EquityIncentivePlanMembersrt:ManagementMember2025-12-310001907223grml:NonEquityIncentivePlanSharesIssuancesMember2026-01-012026-09-300001907223srt:PresidentMember2026-01-012026-09-300001907223grml:NonEquityIncentivePlanSharesIssuancesMember2026-02-142026-02-140001907223grml:NonEquityIncentivePlanSharesIssuancesMember2026-02-192026-02-190001907223grml:NonEquityIncentivePlanSharesIssuancesMember2025-01-012025-12-310001907223grml:NonEquityIncentivePlanSharesIssuancesMember2025-12-310001907223grml:NonEquityIncentivePlanSharesIssuancesMember2024-01-012024-12-310001907223grml:NonEquityIncentivePlanSharesIssuancesMembergrml:Granted2024Member2025-01-012025-12-310001907223grml:NonEquityIncentivePlanSharesIssuancesMembergrml:Granted2024Member2025-12-310001907223grml:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2026-03-020001907223us-gaap:WarrantMembergrml:SecuritiesPurchaseAgreementMember2026-03-020001907223grml:SecuritiesPurchaseAgreementMember2026-03-022026-03-020001907223grml:June2026PrivatePlacementMember2026-06-150001907223grml:June2026PrivatePlacementMember2026-06-152026-06-150001907223grml:AnorTechShareExchangeMember2026-06-220001907223grml:ConsultingAgreementMemberus-gaap:CommonStockMember2026-02-012026-02-280001907223grml:ConsultingWarrantMember2026-02-282026-02-280001907223grml:PrivatePlacementWarrantsMember2026-09-210001907223grml:PrivatePlacementWarrantsMember2026-09-212026-09-2200019072232026-09-232026-09-230001907223grml:PrivatePlacementWarrantsMember2026-09-212026-09-210001907223grml:PrivatePlacementWarrantsMember2026-06-300001907223grml:WarrantsExerciseMemberus-gaap:CommonStockMember2026-09-212026-09-210001907223grml:WarrantsExerciseMemberus-gaap:AdditionalPaidInCapitalMember2026-09-212026-09-210001907223grml:ConsultingWarrantMember2026-09-212026-09-210001907223grml:ConsultingWarrantMember2026-09-222026-09-220001907223grml:August2026RegisteredDirectOfferingMember2026-08-272026-08-270001907223grml:August2026RegisteredDirectOfferingMember2026-08-270001907223grml:PreFundedWarrantsMembergrml:August2026RegisteredDirectOfferingMember2026-08-272026-08-270001907223grml:PreFundedWarrantsMembergrml:August2026RegisteredDirectOfferingMember2026-08-270001907223grml:PreFundedWarrantsMembergrml:August2026RegisteredDirectOfferingMember2026-08-272026-09-280001907223grml:PreFundedWarrantsMembergrml:August2026RegisteredDirectOfferingMember2026-09-300001907223grml:August2026RegisteredDirectOfferingMember2026-09-300001907223grml:September2026RegisteredDirectOfferingsMember2026-09-230001907223grml:September2026RegisteredDirectOfferingsMember2026-09-232026-09-230001907223grml:September2026RegisteredDirectOfferingsMember2026-09-282026-09-280001907223grml:September2026RegisteredDirectOfferingsMember2026-09-280001907223grml:September2026RegisteredDirectOfferingsMember2026-01-012026-09-300001907223grml:WarrantInducementMembersrt:MaximumMember2025-12-310001907223grml:WarrantInducementMembersrt:MinimumMember2025-12-3100019072232025-01-012025-12-310001907223us-gaap:WarrantMember2025-12-310001907223us-gaap:WarrantMember2025-01-012025-12-310001907223grml:AustriaCapitalLLCConvertiblePromissoryNoteMember2025-09-300001907223grml:AustriaCapitalLLCConvertiblePromissoryNoteMember2025-07-012025-09-300001907223grml:AustriaCapitalLLCConvertiblePromissoryNoteMember2025-01-012025-12-310001907223grml:ThreeiNoteConversionMember2025-01-012025-12-310001907223grml:ThreeiNoteConversionMembersrt:MinimumMember2025-01-012025-12-310001907223grml:ThreeiNoteConversionMembersrt:MaximumMember2025-01-012025-12-310001907223grml:SecuritiesPurchaseAgreementMember2025-06-052025-06-050001907223us-gaap:PreferredClassBMember2025-06-090001907223us-gaap:PreferredClassBMemberus-gaap:CommonStockMember2025-06-092025-06-090001907223us-gaap:PreferredClassBMember2025-01-012025-12-310001907223us-gaap:PreferredClassBMemberus-gaap:CommonStockMember2025-01-012025-12-310001907223us-gaap:SeriesCPreferredStockMember2026-03-040001907223us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMember2026-03-042026-03-040001907223us-gaap:SeriesCPreferredStockMembergrml:PublicStockOfferingSharesFromExistingShareholdersMember2026-03-040001907223us-gaap:SeriesCPreferredStockMemberus-gaap:OverAllotmentOptionMember2026-03-0400019072232026-09-032026-09-030001907223grml:SarfartoqAcquisitionOfNeoNorthStarResourcesInc.Membergrml:SeriesRConvertiblePreferredStockMember2026-09-010001907223grml:SeriesRConvertiblePreferredStockMember2026-09-010001907223grml:EmployeeAwardsMember2026-03-012026-03-010001907223grml:EmployeeAwardsMember2026-06-300001907223grml:EmployeeAwardsMember2026-08-240001907223grml:EmployeeAwardsMember2026-01-012026-09-300001907223grml:EmployeeAwardsMember2026-04-012026-06-300001907223grml:EmployeeAwardsMember2026-07-012026-09-300001907223us-gaap:RelatedPartyMembergrml:ForwardSharePurchaseAgreementMember2024-09-302024-09-300001907223grml:ForwardSharePurchaseAgreementMember2024-09-190001907223grml:ForwardSharePurchaseAgreementMember2025-01-012025-03-310001907223grml:ForwardSharePurchaseAgreementMember2025-03-310001907223grml:ForwardSharePurchaseAgreementMember2025-05-152025-05-150001907223grml:ForwardSharePurchaseAgreementMember2025-05-150001907223grml:ForwardSharePurchaseAgreementMember2025-09-012025-09-300001907223grml:ForwardSharePurchaseAgreementMember2025-09-300001907223grml:ForwardSharePurchaseAgreementMember2025-01-012025-12-310001907223grml:ForwardSharePurchaseAgreementMember2025-12-310001907223grml:SaleOfStockTrancheOneMembergrml:ForwardSharePurchaseAgreementMember2026-01-012026-03-310001907223grml:SaleOfStockTrancheOneMembergrml:ForwardSharePurchaseAgreementMember2026-03-310001907223grml:SaleOfStockTrancheTwoMembergrml:ForwardSharePurchaseAgreementMember2026-01-012026-03-310001907223grml:SaleOfStockTrancheTwoMembergrml:ForwardSharePurchaseAgreementMember2026-03-310001907223grml:ForwardSharePurchaseAgreementMember2026-01-012026-03-310001907223grml:ForwardSharePurchaseAgreementMember2026-09-182026-09-180001907223grml:AGPMembergrml:AtTheMarketSalesAgreementMember2025-07-032025-07-030001907223grml:AtTheMarketSalesAgreementMember2025-01-012025-12-310001907223grml:AtTheMarketSalesAgreementMember2025-12-310001907223grml:AtTheMarketSalesAgreementMember2026-01-012026-06-300001907223grml:AtTheMarketSalesAgreementMember2026-06-300001907223grml:August2026AtTheMarketSalesMember2026-08-012026-08-310001907223grml:August2026AtTheMarketSalesMember2026-08-252026-08-250001907223grml:August2026AtTheMarketSalesMember2026-08-2500019072232026-08-2400019072232026-08-2300019072232026-09-012026-09-0100019072232026-08-242026-09-0200019072232026-06-1700019072232026-06-302026-06-300001907223srt:MaximumMember2026-06-182026-06-180001907223srt:MinimumMember2026-06-182026-06-1800019072232026-06-182026-06-180001907223grml:BiotechMemberus-gaap:OperatingSegmentsMember2026-07-012026-09-300001907223grml:MiningMemberus-gaap:OperatingSegmentsMember2026-07-012026-09-300001907223us-gaap:OperatingSegmentsMember2026-07-012026-09-300001907223grml:BiotechMemberus-gaap:OperatingSegmentsMember2025-07-012025-09-300001907223us-gaap:OperatingSegmentsMember2025-07-012025-09-300001907223us-gaap:CorporateNonSegmentMember2026-07-012026-09-300001907223us-gaap:CorporateNonSegmentMember2025-07-012025-09-300001907223grml:BiotechMemberus-gaap:OperatingSegmentsMember2026-01-012026-09-300001907223grml:MiningMemberus-gaap:OperatingSegmentsMember2026-01-012026-09-300001907223us-gaap:OperatingSegmentsMember2026-01-012026-09-300001907223grml:BiotechMemberus-gaap:OperatingSegmentsMember2025-01-012025-09-300001907223us-gaap:OperatingSegmentsMember2025-01-012025-09-300001907223us-gaap:CorporateNonSegmentMember2026-01-012026-09-300001907223us-gaap:CorporateNonSegmentMember2025-01-012025-09-300001907223grml:MiningMember2026-09-300001907223grml:MiningMember2025-12-310001907223grml:BiotechMember2026-09-300001907223grml:BiotechMember2025-12-3100019072232026-01-012026-02-280001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMember2026-11-062026-11-060001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMembergrml:GREENLANDMINESLTDMember2026-11-060001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMember2026-11-060001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMember2026-11-060001907223grml:AnorTechIncMember2026-09-300001907223grml:AnorTechIncMember2026-09-300001907223us-gaap:SubsequentEventMember2026-11-120001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMembergrml:GREENLANDMINESLTDMember2026-11-120001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMember2026-11-120001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMembergrml:GREENLANDMINESLTDMember2026-11-062026-11-060001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMembergrml:SaleOfStockTrancheOneMember2026-11-062026-11-060001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMembergrml:SaleOfStockTrancheTwoMember2026-11-062026-11-060001907223us-gaap:SubsequentEventMembergrml:AnorTechIncMember2026-11-050001907223us-gaap:SubsequentEventMember2026-11-050001907223us-gaap:SubsequentEventMember2026-11-060001907223us-gaap:SubsequentEventMembergrml:BatteryMineralResourcesCorp.BMRMember2026-11-120001907223us-gaap:SubsequentEventMembergrml:BatteryMineralResourcesCorp.BMRMember2026-11-120001907223us-gaap:SubsequentEventMember2026-11-122026-11-120001907223us-gaap:SubsequentEventMembergrml:ShareRepurchaseProgramOctober2026Member2026-10-050001907223us-gaap:SubsequentEventMembergrml:MojoBioPharmaInc.MojoMember2026-11-162026-11-160001907223us-gaap:SubsequentEventMembergrml:MojoBioPharmaInc.MojoMember2026-10-120001907223us-gaap:SubsequentEventMemberus-gaap:CommonStockMember2026-11-132026-11-13
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission file number: 001-41340
GREENLAND MINES LTD
(Exact name of registrant as specified in its charter)
Delaware
86-2727441
(State or other jurisdiction of
 incorporation or organization)
(I.R.S. Employer
 Identification No.)
1300 South Boulevard, Unit D
Charlotte, NC 28203
(Address of principal executive offices) (Zip Code)
(833) 931-6330
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockGRML
The Nasdaq Stock Market LLC
WarrantsGRMLW
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 12, 2026, there were 14,819,209 shares of the registrant’s common stock, $0.0001 par value, issued and outstanding.


Table of Contents
GREENLAND MINES LTD
(formerly known as KLOTHO NEUROSCIENCES, INC.)
FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
Page
PART I. FINANCIAL INFORMATION
1
ITEM 1.
Financial Statements
1
Condensed Consolidated Balance Sheets at September 30, 2026 (Unaudited) and December 31, 2025
1
Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025
2
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2026 and 2025
3
Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025
4
Notes to Unaudited Condensed Consolidated Financial Statements
5
ITEM 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
30
ITEM 3.
Quantitative and Qualitative Disclosures about Market Risk
40
ITEM 4.
Controls and Procedures
40
PART II. OTHER INFORMATION
42
ITEM 1.
Legal Proceedings
42
ITEM 1A.
Risk Factors
42
ITEM 2.
Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
42
ITEM 3.
Defaults Upon Senior Securities
42
ITEM 4.
Mine Safety Disclosures
42
ITEM 5.
Other Information
42
ITEM 6.
Exhibits
43
SIGNATURES
44
i

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
GREENLAND MINES LTD
(formerly known as KLOTHO NEUROSCIENCES, INC.)
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,
2026
December 31,
2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$57,393,437 $7,176,615 
Prepaid expenses1,750,599 117,071 
Other current assets317,006 - 
Total current assets59,461,042 7,293,686 
Other assets:
Intangibles, net74,109,605 2,299,554 
Investment in equity securities3,682,800 - 
Property, plant and equipment, net440,457 - 
Total other assets78,232,862 2,299,554 
Total assets$137,693,904 $9,593,240 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$387,452 $44,607 
Accrued expenses569,130 32,157 
Total current liabilities956,582 76,764 
Derivative liability392,199 53,000 
Total liabilities1,348,781 129,764 
Commitments and contingencies (Note 11)
STOCKHOLDERS’ EQUITY
Preferred stock, par value $0.0001, 100,000,000 shares authorized; 407,264 and 0 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
41 - 
Common stock, par value $0.0001, 1,000,000,000 shares authorized; 13,685,941 and 1,479,826 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
1,369 148 
Common stock to be issued- 516,000 
Additional paid-in capital188,642,526 30,061,801 
Accumulated deficit(52,298,813)(21,114,473)
Total stockholders’ equity136,345,123 9,463,476 
Total liabilities and stockholders’ equity$137,693,904 $9,593,240 
The Company's common stock outstanding as of January 1, 2025 and all share amounts through June 30, 2026 have been retroactively restated for the effect of the 1-for-50 reverse stock split effective August 24, 2026. Fractional shares were rounded up and are included in the restated share amounts
See accompanying notes to the unaudited condensed consolidated financial statements
1

Table of Contents
GREENLAND MINES LTD
(formerly known as KLOTHO NEUROSCIENCES, INC.)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the
 Three Months
 Ended
September 30,
2026
For the
 Three Months
 Ended
September 30,
2025
For the
 Nine Months
 Ended
September 30,
2026
For the
 Nine Months
 Ended
September 30,
2025
Operating expenses:
Professional fees$4,229,757 $711,169 $11,160,880 $2,372,435 
General and administrative1,468,594 868,830 8,258,865 2,213,254 
Research and development409,521 273,305 1,131,328 747,435 
Exploration and evaluation6,304,794 - 6,865,824 - 
Total operating expenses12,412,666 1,853,304 27,416,897 5,333,124 
Net operating loss(12,412,666)(1,853,304)(27,416,897)(5,333,124)
Other income (expense):
Interest expense(4,950)(1,177,999)(11,453)(3,491,961)
Change in fair value of derivative liability(815,660)79,447 (1,314,780)(28,514)
Impairment expense- - (2,045,253)- 
Other income (expense)(408,801)56,271 (395,957)79,603 
Total other income (expense)(1,229,411)(1,042,281)(3,767,443)(3,440,872)
Net loss before income taxes(13,642,077)(2,895,585)(31,184,340)(8,773,996)
Income taxes- - - - 
Net loss$(13,642,077)$(2,895,585)$(31,184,340)$(8,773,996)
Net loss per share: Basic and Diluted$(2.51)$(2.39)$(9.39)$(10.64)
Weighted average common shares outstanding5,438,2271,212,1603,319,799824,496
The Company's common stock outstanding as of January 1, 2025 and all share amounts through June 30, 2026 have been retroactively restated for the effect of the 1-for-50 reverse stock split effective August 24, 2026. Fractional shares were rounded up and are included in the restated share amounts.
See accompanying notes to the unaudited condensed consolidated financial statements.

2

Table of Contents
GREENLAND MINES LTD
(formerly known as KLOTHO NEUROSCIENCES, INC.)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
Common StockPreferred Stock
 (Series B, C, D and R)
Additional
Paid-in
Capital
Common Stock to be
Issued
Accumulated
Deficit
Total
Stockholder’s
Equity
SharesAmountSharesAmount
Balance, January 1, 2025552,480 $55 - $- $11,748,089 $- $(10,562,799)$1,185,345 
Share-based compensation- - - - 495,500 - - 495,500 
Issuance of shares for note payable conversions29,168 3 - - 466,166 - - 466,169 
Issuance of equity warrants in connection with convertible debt- - - - 679,577 - - 679,577 
Termination of shares issued during merger under FPA agreement- - - - 46,100 - - 46,100 
Net loss- - - - - - (2,116,726)(2,116,726)
Balance, March 31, 2025581,648 58 - - 13,435,432 - (12,679,525)755,965 
Share-based compensation8,160 1 - - 390,194 - - 390,195 
Issuance of common shares in connection with note conversions134,316 14 - - 1,226,099 - - 1,226,113 
Issuance of common shares in connection with warrant exercises223,568 22 - - 9,863,287 - - 9,863,309 
Issuance of common shares in connection with stock subscriptions127,507 13 - - 499,987 - - 500,000 
Termination of shares issued during merger under FPA agreement- - - - 94,472 - - 94,472 
Issuance of Preferred B stock for cash- - 500 - 500,000 - - 500,000 
Deemed dividend - warrant modification- - - - 1,530,910 - - 1,530,910 
Net loss- - - - - - (3,761,685)(3,761,685)
Balance at June 30, 20251,075,199 108 500 - 27,540,381 $- (16,441,210)11,099,279 
Share-based compensation12,418 $1 - - 639,585 $- - 639,586 
Conversion of Preferred B Shares to common stock127,507 13 (500)- (13)- - - 
Issuance of common shares in connection with warrant exercises- - - - - - - - 
Discretionary share issuance41,272 4 - - (4)- - - 
Debt conversion settlement40,802 4 - - 1,177,996 - - 1,178,000 
Subscription receivable- - - - 349,475 - - 349,475 
Forward share purchase contract137,605 13 - - (13)- - - 
Issuance of common shares under the At-the-Market facility102- - - 5300- - 5300
Net loss- - - - - - (2,895,585)(2,895,585)
Balance at September 30, 20251,434,905 $143 - $- $29,712,707 $- $(19,336,795)$10,376,055 
Common StockPreferred Stock
 (Series B, C, D and R)
Additional
Paid-in
Capital
Common Stock to be
Issued
Accumulated
Deficit
Total
Stockholder’s
Equity
SharesAmountSharesAmount
Balance, January 1, 20261,479,826 $148 - $- $30,061,801 $516,000 $(21,114,473)$9,463,476 
Share-based compensation
- employees102,005 10 - - 2,085,920 - - 2,085,930 
- non-employees186,670 19 - - 3,537,450 (516,000)- 3,021,469 
Termination of shares issued during merger under FPA agreement- - - - 412,329 - - 412,329 
Issuance of preferred shares in connection with asset acquisition- - 47,940 5 47,939,995 - - 47,940,000 
Issuance of common shares for cash704,896 70 - - 2,402,489 - - 2,402,559 
Net loss- - - - - - (13,857,203)(13,857,203)
Balance at March 31, 20262,473,397 247 47,940 5 86,439,984 - (34,971,676)51,468,560 
Share-based compensation - employees6,557 1 - - 111,081 - - 111,082 
Issuance of common shares in connection with warrant exercises10 - - - 1,745 - - 1,745 
Issuance of common shares for cash507,784 51 - - 6,324,674 - - 6,324,725 
Issuance of common shares in connection with Anortech share exchange252,973 25 - - 3,682,775 - - 3,682,800 
Net loss- - - - - - (3,685,060)(3,685,060)
Balance at June 30, 20263,240,721 324 47,940 5 96,560,259 - (38,656,736)57,903,852 
Share-based compensation
      - employees- - - - 13,875 - - 13,875 
      - non-employees- - - - 893,500 - - 893,500 
Termination of shares issued during merger under FPA agreement
- - - - 306,304 - - 306,304 
Issuance of common shares for cash8,663,505 867 - - 75,396,541 - - 75,397,408 
Issuance of common shares and Series R preferred shares for Sarfartoq acquisition 1,040,676 104 359,324 36 5,443,905 - - 5,444,045 
Issuance of common shares in connection with warrant exercises741,039 74 - - 10,028,142 - - 10,028,216 
Net loss- - - - - - (13,642,077)(13,642,077)
Balance at September 30, 202613,685,941 1,369 407,264 41 188,642,526 - (52,298,813)136,345,123 
The Company's common stock outstanding as of January 1, 2025 and all share amounts through June 30, 2026 have been retroactively restated for the effect of the 1-for-50 reverse stock split effective August 24, 2026. Fractional shares were rounded up and are included in the restated share amounts.
See accompanying notes to the unaudited condensed consolidated financial statements.

3

Table of Contents
GREENLAND MINES LTD
(formerly known as KLOTHO NEUROSCIENCES, INC.)
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Nine Months Ended September 30,
20262025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(31,184,340)$(8,773,996)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
10,988 — 
Changes in fair value of derivative liability1,314,780 28,514 
Impairment on intangible assets2,045,253 - 
Interest expense and debt conversion settlement, net(11,708)3,505,712 
Share-based compensation6,125,856 1,525,281 
Loss on termination of forward purchase agreement (shares)306,304 0
Changes in operating assets and liabilities:
Prepaid expenses(1,631,990)7,767 
Accounts payable342,246 (28,781)
Accrued expenses536,973 (854,109)
Notes payable to related parties- (31,000)
Other current assets(84,881)10,222 
Net cash used in operating activities$(22,230,519)$(4,610,390)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment(451,445)- 
Acquisition of mineral rights and exploratory licenses - Skaergaard(476,474)- 
Acquisition of mineral rights and exploratory licenses - Sarfartoq(19,995,724)- 
Net cash used in investing activities$(20,923,643)$- 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from registered offerings and at-the-market sales of common stock and warrants, net of issuance costs77,972,133 5,300 
Proceeds from private placements and other issuances of equity securities, net of issuance costs11,500,000 12,394,218 
Proceeds from exercise of warrants and pre-funded warrants3,706,940 - 
Proceeds from forward purchase agreement (FPA) settlement412,329 140,572 
Proceeds from convertible promissory note, net of issuance cost- 2,150,000 
Payments on notes payable(220,418)(2,730,182)
Payments for deferred financing costs- (25,000)
Payments on financed director and officer insurance- (40,225)
Net cash provided by financing activities$93,370,984 $11,894,683 
NET CHANGE IN CASH50,216,822 7,284,293 
Cash and cash equivalents - Beginning of period7,176,615 63,741 
Cash and cash equivalents - End of period$57,393,437 $7,348,034 
SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES:
Note payable settled with issuance of common stock$- $1,473,441 
Conversion of debt to equity$- $448,802 
Reversal of OID$- $681,506 
Interest payable settled with issuance of common stock$- $57,641 
Issuance of warrants$- $679,577 
Non-cash acquisition of mineral licenses with common and preferred shares$53,384,045 $- 
Investment in equity securities$3,682,800 $- 
Reclassification of warrant liability to equity upon warrant exercise$6,323,021 $- 
Termination of SPA shares$306,304 
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest Paid$1,871 $79,153 
Taxes Paid$- $- 
See accompanying notes to the unaudited condensed consolidated financial statements.
4

Table of Contents
GREENLAND MINES LTD
(formerly known as KLOTHO NEUROSCIENCES, INC.)
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION
Greenland Mines Ltd (the “Company” or “Greenland Mines”), formerly known as Klotho Neurosciences, Inc., operates through two reportable segments: 1) Biotech, including the Company’s KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS); and 2) Mining, which holds two projects: (a) Skaergaard, focused on the exploration and development of the Skaergaard Project, an undeveloped palladium, gold, and platinum deposit in Southeast Greenland; and (b) Sarfartoq, focused on the exploration and development of the Sarfartoq Project, a neodymium-praseodymium rare earth element deposit in Southwest Greenland acquired September 1, 2026. Through its March 2026 acquisition of Greenland Mines Corp., the Company holds an 80% indirect interest in the Skaergaard Project, which is an exploration-stage mineral property. Pursuant to the Company’s initial S-K 1300 Technical Report Summary with an effective date of July 3, 2026, the Skaergaard Project contains estimated Indicated Mineral Resources of 153.6 million tons at 3.04 g/t palladium equivalent and Inferred Mineral Resources of 177.5 million tons at 3.07 g/t palladium equivalent. Pursuant to the Company’s S-K 1300 Technical Report Summary with an effective date of July 31, 2026, the Sarfartoq Project contains estimated Indicated Mineral Resources of 6.9 million tons at 1.60% total rare earth oxide (“TREO”) and Inferred Mineral Resources of 5.3 million /tons at 0.96% TREO. Mineral resources are not mineral reserves and do not have demonstrated economic viability. Inferred Mineral Resources have a lower level of geological confidence than Indicated Mineral Resources and are considered too speculative geologically to have economic considerations applied to them. The Company has not established any Mineral Reserves at the Skaergaard Project or the Sarfartoq Project, as defined under Regulation S-K Subpart 1300. The Company has reported initial mineral resource estimates for both projects in Technical Report Summaries effective July 3, 2026 (Skaergaard) and July 31, 2026 (Sarfartoq).

On May 30, 2023, Redwoods Acquisition Corp. (“Redwoods”), a Delaware special purpose acquisition company, entered into a Business Combination Agreement with ANEW Medical, Inc. (“ANEW”), a Wyoming corporation, and related merger subsidiaries, pursuant to which the parties consummated a business combination on June 21, 2024. Following the closing, ANEW continued as the surviving corporation and became a wholly owned subsidiary of Redwoods, and Redwoods changed its name to “ANEW Medical, Inc.” For accounting purposes, the transaction was treated as a reverse acquisition, with ANEW deemed the accounting acquirer and Redwoods treated as the acquired company for financial reporting purposes. Accordingly, the transaction was accounted for as a recapitalization, with the net assets of Redwoods recorded at historical cost and no goodwill or intangible assets recognized. Effective September 17, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc.
On March 4, 2026, the Company entered into an Agreement and Plan of Merger with Greenland Mines Corp., pursuant to which a wholly owned merger subsidiary of the Company was merged with and into Greenland Mines, with Greenland Mines surviving the merger as a wholly owned subsidiary of the Company. Following the closing of the transaction, the Company acquired control of Greenland Mines through this forward merger structure. For accounting purposes, the transaction was evaluated under ASC 805 and determined to represent an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in mineral exploration rights and exploratory licenses. Accordingly, the transaction was accounted for as an asset acquisition, with the purchase price allocated to the acquired assets based on relative fair values and no goodwill recognized.
Effective March 11, 2026, the Company changed its name from Klotho Neurosciences, Inc. to Greenland Mines Ltd.
In connection with the Company’s name change, the stock symbol for the Company’s common stock was changed and the Company’s common stock and warrants began trading under the symbols “GRML” and “GRMLW” on the Nasdaq Capital Market at the start of trading on March 12, 2026. The CUSIP number for the Company’s common stock remains unchanged.
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company prepared the Financial Statements, without audit, pursuant to the rules and regulations of the SEC applicable to quarterly reporting on Form 10-Q and reflect, in management’s opinion, all adjustments necessary to present fairly the financial information. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in
5

Table of Contents
financial statements, prepared in accordance with generally accepted accounting principles, have been condensed or omitted as permitted by such rules and regulations. These Financial Statements should be read in conjunction with the consolidated financial statements and related notes included in the 2025 Annual Report. Results of operations for interim periods are not necessarily indicative of annual results.
Reverse Stock Split

On August 24, 2026, following stockholder approval on June 18, 2026, the Company effected a 1-for-50 reverse stock split of its issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split did not change the par value of $0.0001 per share or the 1,000,000,000 authorized shares of the Company’s common stock. Fractional shares held at the beneficial holder level were rounded up to the next whole share. The round-up shares were allocated to the pre-split periods presented in proportion to the shares issued in each. The exercise prices of outstanding warrants and the number of shares issuable on exercise were adjusted in proportion to the Reverse Stock Split. As a result of the Reverse Stock Split, unless described otherwise, all references to common stock, share data, per share data, warrant and option data and related information in these condensed consolidated financial statements and notes have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented, as if it had been effective at the beginning of the earliest period presented. The par value of common stock and additional paid-in capital for each period presented have been restated for the effect of the Reverse Stock Split, with no effect on total stockholders’ equity. See Note 10 – Stockholders’ Equity.

Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Going Concern
The accompanying condensed consolidated financial statements have been prepared on a going concern basis. We have incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2026, we had cash and cash equivalents of approximately $57.4 million and an accumulated deficit of approximately $52.3 million. In accordance with ASC 205-40, management evaluated whether conditions or events, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. Based on our cash balance and our forecast of cash spend through September 30, 2027, which assumes no additional financing, management concluded that our cash and cash equivalents are sufficient to fund our planned operations for at least twelve months from the date these financial statements are issued and that substantial doubt does not exist. We expect to continue to incur operating losses and expect to need additional capital over the longer term to fund the exploration, evaluation and development of our mineral properties.

Reclassification
Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations and were not material. Share-based compensation expense, which was presented as a separate line in the prior year statements of operations ($639,586 and $1,525,281 for the three and nine months ended September 30, 2025), is included in general and administrative expenses ($637,426 and $1,287,691) and research and development expenses ($2,160 and $237,590) for the three and nine months ended September 30, 2025, respectively.

Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage of $250,000. As of September 30, 2026, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Foreign Currency
The Company’s reporting currency is the U.S. dollar, and the functional currency of the Company and its subsidiaries is the U.S. dollar. Transactions denominated in currencies other than the functional currency, including Canadian dollars, Danish kroner, and Euros, are remeasured into U.S. dollars at the exchange rates in effect on the transaction date. Monetary assets and liabilities denominated in foreign currencies are remeasured at the exchange rates in effect at the balance sheet date.
6

Table of Contents
Gains and losses arising from foreign currency transactions and remeasurement are recognized in other income (expense) in the condensed consolidated statements of operations.
Fair Value of Financial Instruments
The assets and liabilities are valued using a fair market basis as defined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Concept (“ASC”) 820, Fair Value Measurement. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company uses a three-level hierarchy established by the FASB that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the fair value hierarchy are described below:
Level 1: Quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3: Unobservable inputs with little or no market data available, which require the reporting entity to develop its own assumptions.
The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Fair value measurements at reporting date using:
Fair value
Quoted prices in active markets
for identical liabilities
 (Level 1)
Significant other observable
inputs
 (Level 2)
Significant unobservable inputs
 (Level 3)
Assets:
Cash equivalents, September 30, 2026$56,559,229 $56,559,229 $- $- 
Cash equivalents, December 31, 2025$7,031,708 $7,031,708 $- $- 
Liabilities:
Derivative liabilities, September 30, 2026$392,199 $- $392,199 $- 
Derivative liabilities, December 31, 2025$53,000 $- $- $53,000 
The following tables present a reconciliation of the Level 3 derivative liability:
For the Three Months Ended
September 30,
20262025
Derivative liabilities, July 1 $5,899,561 $132,447 
Change in fair value 815,660 (79,447)
Settlement of warrants upon exercise(6,323,022)- 
Transfer to Level 2(392,199)- 
Derivative liabilities, September 30$- $53,000 
7

Table of Contents
For the Nine Months Ended
September 30,
20262025
Derivative liabilities, January 1 $53,000 $24,486 
Additions 5,347,441 - 
Change in fair value1,314,780 28,514 
Settlement of warrants upon exercise$(6,323,022)$- 
Transfer to Level 2$(392,199)$- 
Derivative liabilities, September 30$- $53,000 
The warrants issued in the March 2026 Private Placement (the “Private Placement Warrants”) were classified in Level 3 until their exercise on September 22, 2026 because the Black-Scholes option pricing model used to determine their fair value required significant unobservable inputs, including expected volatility and expected life. In determining the fair value of the Private Placement Warrants, the Company used the following inputs as of June 30, 2026, the last quarter-end at which they were outstanding:

June 30, 2026
Risk-free interest rate4.19 %
Expected dividend yield0%
Expected volatility129.18 %
Expected life4.6 years
On September 22, 2026, the Company remeasured the 691,039 Private Placement Warrants exercised to fair value immediately before settlement and recognized the change in fair value in earnings. Because the warrants were exercised on that date, no meaningful time value remained, and the Company measured them at intrinsic value: the closing price of the Company’s common stock of $14.15 less the $5.00 exercise price, or $9.15 per warrant, for a fair value of $6,323,022. The liability was reclassified to additional paid-in capital. See Note 11.

The 530,000 private warrants assumed in the June 2024 business combination with Redwoods Acquisition Corp. (the “Legacy Private Warrants”) are classified as liabilities. The Company measures them using the closing price of its publicly traded warrants (Nasdaq: GRMLW) on the measurement date, which was $0.74 per warrant at September 30, 2026. The 530,000 warrants are stated before adjustment for the Reverse Stock Split, and the Company applies the quoted price per warrant to that number of warrants. As adjusted for the Reverse Stock Split, the 530,000 warrants are exercisable for 10,600 shares of common stock in the aggregate. The quoted price is an observable input for a similar, but not identical, instrument, so the Company classifies the Legacy Private Warrants in Level 2 of the fair value hierarchy. The Legacy Private Warrants were transferred out of Level 3 as of September 30, 2026 at their fair value of $392,199. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period in which they occur.

Consideration transferred in the Company’s asset acquisitions (Note 3) is measured at fair value once, at the acquisition date, to determine the cost of the assets acquired. These amounts are not remeasured, and the acquired mineral rights and exploration licenses are carried at cost less impairment, therefore they are not included in the fair value hierarchy table above. The common stock issued in the Sarfartoq acquisition was measured at the observable closing price of the Company’s common stock on the acquisition date, adjusted for a discount for lack of marketability, and the Series R Convertible Preferred Stock was measured using a probability-weighted analysis that also includes a discount for lack of marketability. The discounts, the probability of stockholder approval, and the expected timing of approval are unobservable inputs (Level 3).

Convertible Preferred Shares
The Company determines the accounting for convertible preferred shares in accordance with ASC 480 and ASC 815. Specifically, the preferred shares will initially be assessed to determine whether they should be classified as a liability. Once it has been determined that they should not be classified as a liability, the Company will assess whether i) they should be classified in permanent or temporary equity and ii) if the conversion option should be bifurcated and recognized as a separate liability. If the conversion option is bifurcated and recognized as a separate liability it will be initially and subsequently measured at fair value.
8

Table of Contents
Warrants
Warrants are accounted for in accordance with ASC 480 and ASC 815. Warrants that are within the scope of ASC 480 will be recognized as a liability and initially measured at fair value and subsequently re-measured to fair value at the end of each reporting period. If the warrants are not within the scope of ASC 480 the Company will then assess whether the warrants are considered indexed to the Company’s stock in accordance with ASC 815-40. If the warrants are considered indexed to the Company’s stock they will be classified in equity. Otherwise, the warrants will be classified as a liability and initially measured at fair value and subsequently re-measured to fair value at the end of each reporting period.
As of September 30, 2026, the fair value of the Derivative liability for the Private Warrants was $392,199, which was based on the quoted price of the Company’s publicly traded warrants (Level 2). The Private Placement Warrants were exercised on September 22, 2026, and no warrants measured using the Black-Scholes option pricing model remain outstanding. During the three months ended September 30, 2026, the fair value of the derivative liability increased by $815,660. During the nine months ended September 30, 2026, the fair value of the derivative liability increased by $1,314,780.

Investments in Equity Securities
The Company accounts for investments in equity securities in accordance with ASC 321, Investments - Equity Securities. Equity securities with a readily determinable fair value are measured at fair value, with changes in fair value recognized in net loss. For equity securities that do not have a readily determinable fair value and over which the Company does not have significant influence, the Company has elected the measurement alternative under ASC 321-10-35-2, under which the investment is measured at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.
Each reporting period, the Company performs a qualitative assessment to determine whether an investment measured under the measurement alternative is impaired. If the qualitative assessment indicates impairment, the Company estimates the fair value of the investment and, if fair value is less than the carrying amount, recognizes an impairment charge in net loss equal to the difference. See Note 6.
Intangible Assets
The Company’s intangible assets consist of acquired medical licenses and patents, and acquired mineral exploration rights and exploration licenses.
Acquired mineral exploration rights and exploration licenses are capitalized at cost and relate to exploration-stage properties that are not yet ready for their intended use. Accordingly, such assets are not amortized. See “Mineral Exploration Rights and Exploration Costs” below.
Mineral Exploration Rights and Exploration Costs
Costs to acquire mineral exploration rights and exploration licenses are capitalized when incurred. Capitalized mineral property acquisition costs relate to exploration-stage properties that are not yet ready for their intended use and, accordingly, are not amortized. Such assets will be amortized on a units-of-production basis if and when the related properties enter production.
Exploration and evaluation costs, including geological and geophysical studies, sampling, drilling, technical studies, and related support costs, are expensed as incurred. Such costs are expensed until technical feasibility and commercial viability of the mineral property have been demonstrated and the property is determined to be economically recoverable. As of September 30, 2026, the Skaergaard Project and Sarfartoq Project contained Mineral Resources, as disclosed in the Company’s S-K 1300 Technical Report Summary effective July 3, 2026 and July 31, 2026, respectively; however, the Company had not established any Mineral Reserves and had not completed the technical and economic studies necessary to demonstrate the project’s economic recoverability. Accordingly, all exploration and evaluation costs incurred during the three and nine months ended September 30, 2026 were expensed as incurred.
Capitalized mineral exploration rights and exploration licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
9

Table of Contents
Impairment of Long-Lived and Intangible Assets
The Company assesses its long-lived and intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable, and at least annually. Factors considered important, which could trigger an impairment review, include significant underperformance relative to historical or projected future cash flows, significant changes in the manner of use of the assets or in the overall business strategy, and significant negative industry trends. When management determines that the carrying value of a long-lived or intangible asset may not be recoverable, impairment is measured as the excess of the asset’s carrying value over its estimated fair value, and an impairment loss is recognized in the condensed consolidated statements of operations in the period identified.
During the nine months ended September 30, 2026, the Company determined that the licenses related to various generic drugs and to four generic drugs (Encore) were fully impaired and recognized impairment expense of $2,045,253. Management determined that these licenses were fully impaired following the Company’s strategic pivot after the March 4, 2026 acquisition of Greenland Mines Corp. As a result of that transaction, the licenses have no alternative future use to the Company. The impairment charge is non-cash and non-recurring. The impairment was recognized during the three months ended March 31, 2026, and no additional impairment was recognized during the three months ended September 30, 2026. The impaired intangible assets were reported within the Biotech segment, and the impairment expense is presented within other income (expense) in the condensed consolidated statements of operations.
The Company evaluated its mineral exploration rights and exploration licenses for impairment as of September 30, 2026. Recoverability of these assets is dependent upon future exploration success, the availability of financing, the receipt of regulatory approvals, and the establishment of economically recoverable reserves. As of September 30, 2026, management did not identify any indicators of impairment with respect to the mineral exploration rights and exploration licenses, and no impairment was recognized. The Company determined that the estimated fair value of all other intangible assets exceeded their carrying value, indicating no impairment.
Property, Plant and Equipment

Property, plant and equipment is stated at cost less accumulated depreciation. Cost includes the purchase price and expenditures directly attributable to bringing an asset to the location and condition necessary for its intended use, including freight, transportation, installation, and preparation costs. The Company capitalizes purchases of equipment, infrastructure, vehicles, and other tangible assets that are expected to provide economic benefits beyond one year, whether or not the related mineral property remains in the exploration stage, and records the asset when it obtains control of it. Amounts paid in advance for such assets are recorded as prepaid expenses until control transfers.

The Company applies a capitalization threshold of $5,000 per unit of account. The unit of account is the lowest level at which an asset can perform its intended function independently; components acquired together that depend on one another to perform a single function are accounted for as a single asset. Expenditures for routine repairs and maintenance are expensed as incurred, while expenditures that extend an asset’s useful life, increase its capacity or improve its efficiency are capitalized.

Depreciation is computed using the straight-line method over the estimated useful lives of the assets, beginning when an asset is placed in service. Assets acquired in used condition are depreciated over their estimated remaining useful lives, considering their age, condition, maintenance history and expected use. Estimated useful lives are reviewed annually and revised prospectively when appropriate, and are as follows:

Camp buildings and infrastructure
7 years
Accommodation and operational containers
5 to 7 years
Vehicles and mobile equipment
5 years
Drilling, laboratory, survey and geophysical equipment
5 years
Drones, communications equipment and computer hardware
3 years
Capitalized tools and small equipment
3 years

The Company had no property, plant and equipment as of December 31, 2025. The assets held as of September 30, 2026 were acquired for the Company’s 2026 exploration field season. Property, plant and equipment consisted of the following:
Useful lifeSeptember 30, 2026December 31, 2025
10

Table of Contents
Camp infrastructure7 years$236,368$-
Field and laboratory equipment5 years139,395 -
Vehicles and field equipment5 years75,682-
Total cost451,445 -
Less: accumulated depreciation(10,988)-
Property, plant and equipment, net$440,457$-

Depreciation expense was $10,988 for both the three and nine months ended September 30, 2026. The Company recorded no depreciation expense for the three and nine months ended September 30, 2025.

The Company evaluates property, plant and equipment for impairment in accordance with ASC 360, Property, Plant, and Equipment, whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. No impairment of property, plant and equipment was recognized during the three and nine months ended September 30, 2026.

Share-based Compensation
The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718 and No. 505. The Company issues restricted stock and stock options to employees and consultants for their services. Costs for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.
The Company recorded share-based compensation of $907,375 and $639,586 for the three months ended September 30, 2026 and 2025, respectively. The Company recorded share-based compensation of $6,125,856 and $1,525,281 for the nine months ended September 30, 2026 and 2025, respectively.
Income Taxes
Following the March 2026 acquisition of Greenland Mines Corp., the Company is subject to income tax filing requirements in U.S. federal, various state, and foreign jurisdictions. The Company has filed its income tax return for the year ended December 31, 2025. The Company’s tax returns for 2023, 2024 and 2025 are subject to examination by U.S. federal, state, and local tax authorities. Foreign tax returns are subject to examination in accordance with the statutes of the applicable jurisdictions.

Net Loss Per Share (Basic and Diluted).
The following table details the net loss per share calculation, reconciles between basic and diluted weighted average shares outstanding, and presents the potentially dilutive shares that are excluded from the calculation of the weighted average diluted common shares outstanding, because their inclusion would have been anti-dilutive:
For the Three Months Ended
September 30,
For the Nine Months Ended
September 30,
2026202520262025
Numerator:
Net loss$(13,642,077)$(2,895,585)$(31,184,340)$(8,773,996)
Weighted-average common shares outstanding, basic and diluted5,438,2271,212,1603,319,799824,496
Basic and diluted loss per share$(2.51)$(2.39)$(9.39)$(10.64)
11

Table of Contents
The following common share equivalents are excluded from the calculation of weighted average common shares outstanding, because their inclusion would have been anti-dilutive:
As of September 30,
20262025
Warrants151,416 101,426 
Preferred Shares C (1)
47,940 - 
Preferred Shares R (2)
359,324 - 
Total potentially dilutive shares558,680 101,426 
(1)The 47,940 shares of Series C Preferred Stock outstanding at September 30, 2026 are each convertible into approximately 851 shares of common stock after adjustment for the 1-for-50 reverse stock split described in Note 10 (42,554 shares before adjustment), or 40,800,775 shares of common stock in the aggregate, only after the conversion limit described in this paragraph ends. The Company’s stockholders approved the issuance of the common stock issuable on conversion at a special meeting held on September 3, 2026. On September 3, 2026, the Company amended the certificate of designation for the Series C Preferred Stock to limit conversion until the earlier of (i) January 8, 2027 and (ii) the next trading day after the fifth consecutive trading day on which the Nasdaq closing price of the common stock is at least $15.00 per share. Neither condition had been met as of September 30, 2026, and accordingly the Series C Preferred Stock was not convertible. The Series C Preferred Stock is presented in the table above as the number of preferred shares outstanding (47,940), not on an as-converted basis; on an as-converted basis it would be 40,800,775 shares of common stock. It is excluded from the computation of diluted net loss per share because its inclusion would have been anti-dilutive. Conversion was also not permitted as of September 30, 2026 under the limit described above. See Note 10.
(2)The 359,324 shares of Series R Convertible Preferred Stock outstanding at September 30, 2026 are each convertible into one share of common stock, or 359,324 shares of common stock in the aggregate, only upon approval by the Company’s stockholders. Such approval had not been obtained as of September 30, 2026, and accordingly the Series R Convertible Preferred Stock was not convertible. The Series R Convertible Preferred Stock is presented in the table above on an as-converted basis and is excluded from the computation of diluted net loss per share because the conversion condition had not been satisfied and, in any event, its inclusion would have been anti-dilutive. See Notes 3 and 10.

Segment Information
Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the Chief Operating Decision Maker (“CODM”) or decision-making group in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as two reportable segments: (i) biotechnology operations focused on research and development activities, and (ii) mining, which includes two projects: the Skaergaard Project, an exploration-stage mineral property in southeast Greenland, and the Sarfartoq Project, an exploration-stage rare earth element property in southwest Greenland acquired September 1, 2026. See Note 12 - Segment Information for additional information.

Recent Accounting Pronouncements
Recently Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of significant segment expenses regularly provided to the chief operating decision maker, an amount for other segment items, and the title and position of the chief operating decision maker. The Company adopted ASU 2023-07 effective January 1, 2024. Adoption did not affect the Company's financial position or results of operations and resulted in expanded segment disclosures. See Note 12.

Issued but Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which requires disaggregated disclosure of certain expense categories within relevant income statement captions. As an emerging growth company that has elected to use the extended transition
12

Table of Contents
period for complying with new or revised accounting standards, the Company expects to adopt this standard in accordance with the effective dates applicable to private companies. The Company is evaluating the effect of adoption on its disclosures.
The Company does not expect that any other recently issued accounting pronouncements will have a material effect on its condensed consolidated financial statements.
NOTE 3 — ACQUISITIONS
1) Skaergaard: Acquisition of Greenland Mines Corp.

Transaction Overview

On March 4, 2026, the Company completed a forward merger pursuant to which Greenland Merger Sub, Inc., a wholly owned subsidiary of the Company, merged with and into Greenland Mines Corp. (“Greenland”), with Greenland surviving as a wholly owned subsidiary (the “Transaction”).
At the acquisition date, Greenland’s assets consisted primarily of mineral exploration rights and early-stage exploration licenses related to the Skaergaard Project in Greenland. Greenland did not have mineral production, revenues, or an organized workforce and the Company concluded that substantially all of the fair value of the assets acquired was concentrated in mineral exploration rights. As such, in accordance with the definition of a business outlined in ASC 805-10-55, the Transaction did not meet the definition of a business and was accounted for as an asset acquisition under ASC 805-50.
The fair value of the consideration transferred, which was more reliably measurable than the fair value of the mineral exploration rights, totaled approximately $48.4 million and was determined as summarized in the table below:
Fair value of consideration transferred
Cash (CAD$500,000 converted in USD)
$365,324 
Fair value of preferred stock C (47,940 shares)
47,940,000 
Total consideration transferred48,305,324 
Transaction costs of the asset acquisition (a)111,150 
Total acquisition costs$48,416,474 
Greenland’s identifiable assets acquired and liabilities assumed
Mineral exploration rights and exploration licenses$48,416,474 
(a)Transaction costs include direct costs to acquire the assets, such as fees paid to external advisors. Indirect costs not directly attributable to the acquisition of the assets have been expensed as incurred.
The following table summarizes the Company’s indefinite lived intangible assets acquired in connection with the Acquisition and their carrying value as of September 30, 2026:
Acquisition
 Date
Level 3
Fair Value
ImpairmentCarrying Value
 as of
September 30,
2026
Mineral exploration rights and exploration licenses$48,416,474 $- $48,416,474 
Total long-lived assets$48,416,474 $- $48,416,474 
13

Table of Contents
Future Development Activities
The Company’s ability to realize value from the acquired mineral interests is dependent on future exploration success, availability of financing, regulatory approvals, technical studies, and the development of mining and processing infrastructure. Costs incurred for ongoing exploration and evaluation activities subsequent to the acquisition date will be accounted for in accordance with the Company’s accounting policies and applicable U.S. GAAP.
Business Plan
The Company’s principal assets consist of mineral exploration rights and exploration licenses related to the Skaergaard Project in Greenland. These mineral properties are non-producing, have not been demonstrated to contain mineral reserves as defined under SEC Regulation S-K Subpart 1300, and have not generated revenues.
The Company’s exploration activities are in an early stage and are focused on evaluating the geological characteristics and mineral potential of the properties. Advancement of the mineral assets is dependent on the results of ongoing and future exploration programs, including geological studies, sampling, and drilling, as well as the completion of technical, environmental, and economic evaluations.
The Company does not have proven or probable mineral reserves and has not determined whether the mineral properties contain economically recoverable mineralization. The establishment of economically recoverable reserves will require additional exploration, permitting, regulatory approvals, and significant capital expenditures. There can be no assurance that the Company’s exploration efforts will result in the identification of mineral reserves, that the properties will be developed into producing mines, or that mining operations will ever commence.
The Company’s mineral rights at the Skaergaard Project are held under three Greenland exploration licenses: MEL 2012-25 and MEL 2021-10, which expire on December 31, 2026, and MEL 2007-01, which expires on December 31, 2027. Management plans to apply to renew each license and expects the renewals to be in the ordinary course of business.

As of September 30, 2026, management has not identified any indicators of impairment related to the Company’s mineral exploration rights and exploration licenses. The mineral properties will continue to be evaluated for impairment in accordance with applicable accounting guidance as exploration activities progress and additional information becomes available.
2) Sarfartoq: Acquisition of NNSR Holdings Inc.

Transaction Overview

On May 20, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire Neo North Star Resources, Inc. (“Neo North Star”), the holder of the Sarfartoq Rare Earth Element Project, a neodymium-praseodymium (“Nd-Pr”) rare earth element exploration property in southwest Greenland (the “Sarfartoq Project”), from its stockholders. On September 1, 2026, the Company entered into an Amendment to the Merger Agreement (this “Amendment”) by and among Company, Greenland Rare Earths Corp., a Delaware corporation (“Merger Sub”), Neo North Star, the stockholders of Neo North Star, and Lazaros Nikeas, as the representative of the stockholders of Neo North Star. The Amendment (a) substituted a new parent entity, NNSR Holdings Inc., a Delaware corporation and sole stockholder of Neo North Star for Neo North Star under the Merger Agreement and (b) fixed the equity consideration payable by the Company under the Merger Agreement as 1,040,676 newly issued shares of Company’s common stock and 359,324 newly issued shares of a newly designated series of the Company’s preferred stock. On September 1, 2026, the Company completed the acquisition (the “Sarfartoq Acquisition”).

At the acquisition date, Neo North Star’s assets consisted primarily of mineral rights and early-stage exploration licenses related to the Sarfartoq Project. Neo North Star did not have mineral production, revenues, or an organized workforce. The Company applied the concentration test in ASC 805-10-55-5A and concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the Sarfartoq mineral exploration license. As a result, the acquired asset was not a business, and the Sarfartoq Acquisition was accounted for as an asset acquisition under ASC 805-50. Under that guidance, the cost of the acquisition, including capitalized transaction costs, is allocated to the assets acquired, and no goodwill is recognized.

At closing, the Company paid $19,882,065 in cash and issued 1,040,676 shares of common stock and the 359,324 shares of Series R Convertible Preferred Stock.

14

Table of Contents
The consideration transferred was $25,326,110, consisting of cash of $19,882,065 and equity with a fair value of $5,444,045. Including $0.1 million of capitalized transaction costs, the cost basis of the Sarfartoq Project mineral property was approximately $25.4 million. Neo North Star held cash of $6,823 at the acquisition date.

The fair value of the consideration transferred ($25,326,110), the total acquisition costs and the allocation of those costs to the mineral rights and exploration license are summarized in the table below:

Cash
$
19,882,065 
Fair value of common stock issued (1,040,676 shares)
4,161,663 
Fair value of Series R Convertible Preferred Stock issued (359,324 shares)
1,282,382 
Total consideration transferred
$
25,326,110 
Transaction costs of the asset acquisition (a)
120,482 
Less: net monetary assets acquired (b)
(7,762)
Total acquisition costs
$
25,438,830 
(a) Transaction costs include direct costs to acquire the assets, such as fees paid to external advisors. Indirect costs not directly attributable to the acquisition of the assets have been expensed as incurred.
(b) Net monetary assets acquired consist of cash of $6,823, prepaid franchise tax of $1,538 and accounts payable of $599.

Neo North Star’s identifiable assets acquired and liabilities assumed, all of which were allocated to the mineral rights and exploration license comprising the Sarfartoq Project, were as follows:

Mineral rights and exploration license—Sarfartoq Project
$
25,438,830

The following table summarizes the Company’s indefinite lived intangible assets acquired in connection with the Sarfartoq Acquisition and their carrying value as of September 30, 2026:

Acquisition Date
Carrying Value as of
Cost
September 30,
Basis
Impairment
2026
Mineral rights and exploration license
$
25,438,830
$
-
$
25,438,830
Total long-lived assets
$
25,438,830
$
-
$
25,438,830

Offtake Agreement with Related Party

In connection with the Sarfartoq Acquisition, the Company entered into a non-binding offtake agreement with Neo Performance Materials, a related party, under which Neo Performance Materials would have the right to purchase up to 60% of future production from the Sarfartoq Project. The agreement does not obligate either party to buy or sell any production, and no amounts have been recorded under it. See Note 9 — Related Parties for further information.

Business Plan

The Company’s principal assets acquired in the Sarfartoq Acquisition consist of mineral rights and exploration licenses related to the Sarfartoq Project in southwest Greenland. This mineral property is non-producing, has not been demonstrated to contain mineral reserves as defined under SEC Regulation S-K Subpart 1300, and has not generated revenues.

The Company’s exploration activities with respect to the Sarfartoq Project are in an early stage and are focused on evaluating the geological characteristics and Nd-Pr rare earth element mineral potential of the property. Advancement of the mineral asset is dependent on the results of ongoing and future exploration programs, including geological studies, sampling, and drilling, as well as the completion of technical, environmental, and economic evaluations.

The Company does not have proven or probable mineral reserves at the Sarfartoq Project and has not determined whether the property contains economically recoverable mineralization. The establishment of economically recoverable reserves
15

Table of Contents
will require additional exploration, permitting, regulatory approvals, and significant capital expenditures. There can be no assurance that the Company’s exploration efforts will result in the identification of mineral reserves, that the property will be developed into a producing mine, or that mining operations will ever commence.

The Company’s mineral rights at the Sarfartoq Project are held under Greenland exploration License No. 2020-32 (MEL 2020-32). On August 19, 2026, by Addendum No. 8, the Government of Greenland approved the indirect transfer of the license, which changes the controlling interest to the Company. The license expires on December 31, 2026, and the Company plans to renew the license.

As of September 30, 2026, management has not identified any indicators of impairment related to the Company’s mineral rights and exploration license for the Sarfartoq Project. The mineral property will continue to be evaluated for impairment in accordance with applicable accounting guidance as exploration activities progress and additional information becomes available.

NOTE 4 — PREPAID EXPENSES
Prepaid expenses consist of prepayment of the premium on Directors and Officers insurance, Nasdaq annual fees, association membership fees, fees related to chartered vessels and equipment for summer fieldwork at the Skaergaard Project, consulting, and Delaware franchise taxes. As of September 30, 2026 and December 31, 2025, prepaid expenses totaled $1,750,599 and $117,071, respectively, in the accompanying condensed consolidated balance sheets.
NOTE 5 — INTANGIBLE ASSETS
Intangible assets consisted of the following:
Intangible AssetsSeptember 30,
2026
December 31,
2025
Licenses
Non-Exclusive License Agreement$179,821 $179,821 
Various generic drugs- 736,983 
Four generic drugs (Encore)- 1,308,270 
Needleless Syringe License26,060 26,060 
Patents48,420 48,420 
Mineral exploration rights and exploration licenses - Skaergaard48,416,474 - 
Mineral exploration rights and exploration licenses - Sarfartoq25,438,830 - 
Total intangible assets, net$74,109,605 $2,299,554 
Intangible assets are as follows:
•Non-Exclusive License Agreement ($179,821) – On March 5, 2023, the Company signed a Non-Exclusive License Agreement with Heidelberg University to grant non-exclusive rights to various licenses owned and under development by the university. The licenses include the use of modified AAV capsid polypeptides for treatment of muscular diseases. The terms include a €50,000 ($56,325) fee for signing the agreement and €100,000 ($112,650) payment within 60 days of the anniversary of signing the agreement. The Company will pay €1,000,000 ($1,126,500) for each assignment of a right to a license owned by the university. For new licenses, the Company will make standard commercial development-based milestone payments for the various stages of license development and regulatory approval. The Company will make 2% royalty payments by January 31st each year during the term of the agreement for each licensed product for the preceding calendar year. The University of Heidelberg license is in good standing. The Company plans to use this license alongside other AAV vectors as part of upcoming clinical trials for KLTO-202. The value of the licenses was $179,821 at both September 30, 2026 and December 31, 2025.
•Various Generic Drugs ($736,983) - During 2015, the Company acquired two licenses for biosimilar biologic therapies to treat cancer and autoimmune diseases from Reliance Life Sciences. The value of the licenses was $736,983 at December 31, 2025. As of December 31, 2025, the licenses remained in good standing and the Company continued to evaluate their future use. Following the Company’s strategic pivot after the March 4, 2026 acquisition of Greenland Mines Corp., management determined during the three months ended March 31, 2026 that these licenses were fully impaired, reducing their carrying value to zero. As a result of that transaction, the
16

Table of Contents
licenses have no alternative future use to the Company, and the impairment charge is non-recurring. No additional impairment was recognized during the three months ended September 30, 2026, and the carrying value of these licenses was $0 at September 30, 2026.
•Four Generic Drugs (Encore) ($1,308,270) – On September 12, 2022, the Company acquired four market-approved anti-cancer drugs approved for sale in Germany for $1,308,270. The purchase price represents the fair value of the intangible asset based on the net present value of the projected gross profit to be generated by the licenses. The value of the licenses was $1,308,270 at December 31, 2025. Following the Company’s strategic pivot after the March 4, 2026 acquisition of Greenland Mines Corp., management determined during the three months ended March 31, 2026, the four generic drugs (Encore) licenses were fully impaired, reducing their carrying value to zero. As a result of that transaction, the licenses have no alternative future use to the Company, and the impairment charge is non-recurring. No additional impairment was recognized during the three months ended September 30, 2026, and the carrying value of these licenses was $0 at September 30, 2026
•Needleless Syringe License ($26,060) – On December 1, 2023, the Company signed a license agreement with TransferTech Sherbrooke for the rights to develop and commercialize the technology of a “Needleless Syringe.” Under the terms of the agreement, the Company paid a $26,060 upfront fee and royalty fees on the license income. The Company has not commenced developing the technology. The license is in good standing. The Company has worked with Sherbrooke to begin advanced prototyping of the device and has plans to fund continued tech development and selection of drug candidates to pair with the device. The value of the license was $26,060 at both September 30, 2026 and December 31, 2025.
•Patents ($48,420) – Through its licensing arrangements, the Company acquires the right to patents for Alzheimer, ALS, and other items. Once the patents are declared effective, patents are amortized using the straight-line method over their estimated useful lives or statutory lives, whichever is shorter, and will be reviewed for impairment upon any triggering event that may impact the assets’ ultimate recoverability as prescribed under the guidance related to impairment of long-lived assets. Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. The patent value, which is included in licenses in the accompanying condensed consolidated balance sheet, was $48,420 at both September 30, 2026 and December 31, 2025.
•Exclusive World-wide License Agreement – On January 24, 2022, the Company signed an exclusive, world-wide License Agreement with the University of Barcelona for a cell and/or gene therapy that has shown compelling activity in animal models of human Alzheimer’s disease and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s disease”). The gene therapy will also be applied to age-related diseases and rare (“Orphan”) diseases. Beginning on December 15, 2022, the annual license fee is 10,000 Euros. In addition, the Company will pay a Royalty equal to 3% of net sales of finished products once the license is in use. The UAB license remains in good standing, and the Company plans to use the license for clinical development of its Klotho pipeline, including KLTO-101 and KLTO-202. As of September 30, 2026 and December 31, 2025, the Company owed $0 under the agreement. No amount has been capitalized with respect to this agreement, and accordingly it is not included in the table above.
•Mineral exploration rights and early-stage exploration licenses ($73,855,304) – The Company holds mineral exploration rights and early-stage exploration licenses related to the Skaergaard Project in Greenland ($48,416,474) and, since the September 1, 2026 acquisition described in Note 3, the Sarfartoq Project in Greenland ($25,438,830). The mineral exploration rights and exploration licenses represent the Company’s rights to explore, develop, and drill and sample mineral resources within the licensed area. As of September 30, 2026, the Company’s intangible assets primarily comprise early-stage exploration assets that are not yet ready for their intended use.

The Company’s medical licenses and patents are not currently in use, as the Company is in the pre-revenue stage, and accordingly are not being amortized. Once these licenses and patents are placed in service, they will be amortized on a straight-line basis over their estimated useful lives. The Company’s mineral exploration rights and exploration licenses relate to exploration-stage properties that are not yet ready for their intended use and are not amortized. Such assets will be amortized on a units-of-production basis if and when the related properties enter production. No amortization expense was recognized for the three and nine months ended September 30, 2026 or 2025.
17

Table of Contents
NOTE 6 — INVESTMENT IN EQUITY SECURITIES
On June 22, 2026, the Company completed a share exchange with AnorTech Inc. (“AnorTech”), a company listed on the TSX Venture Exchange that is engaged in the development of processing technologies for alumina and related industrial materials derived from its anorthosite project in Greenland. Pursuant to the exchange, the Company issued 248,000 shares of its common stock in exchange for 19,958,503 common shares of AnorTech, representing approximately 9.9% of AnorTech’s outstanding common stock following the issuance. The Company made the investment to obtain exposure to downstream processing activities complementary to its mineral exploration operations in Greenland. The statement of changes in stockholders’ equity presents 252,973 shares for this issuance, which is the 248,000 shares issued plus 4,973 shares allocated to it from the round-up of fractional shares in the August 24, 2026 reverse stock split (see Note 2 and Note 10). The investment was measured on the 248,000 shares issued.
In connection with the exchange, the Company also received an option to acquire up to an additional 25,168,669 common shares of AnorTech, which, if exercised in full, would increase the Company’s ownership interest to approximately 19.9%. The option is exercisable in full only, for a period of six months from June 22, 2026, at an exercise price equal to the greater of CAD$0.30 per share or the last closing price of AnorTech’s shares on the TSX Venture Exchange, payable in shares of the Company’s common stock valued at a volume-weighted average price.
AnorTech is not a related party, and the Company does not have significant influence over AnorTech. Accordingly, the investment is accounted for as an equity security under ASC 321, Investments in Equity Securities, and not under the equity method.
The Company’s investment in AnorTech common stock does not have a readily determinable fair value. The shares are subject to a 60-month contractual lock-up, in addition to a four-month Canadian statutory hold period, and under ASC 321-10-20 a restricted security has a readily determinable fair value only if the restriction terminates within one year. Accordingly, the Company elected to measure the investment using the measurement alternative in ASC 321-10-35-2, at cost less any impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer. Although AnorTech’s common shares are quoted on the TSX Venture Exchange and the OTCQB, trading in those markets is limited and sporadic and does not constitute an active market. Accordingly, the Company does not remeasure the investment to such quoted prices and does not consider those quotations, on their own, to represent observable price changes in orderly transactions for an identical or similar investment.
The exchange was a nonmonetary transaction. Because the AnorTech shares received do not have a reliably determinable fair value, the Company measured the investment based on the fair value of the consideration given, which was more reliably measurable. The 248,000 shares of the Company’s common stock issued were valued at the closing price of the Company’s common stock on June 22, 2026 of $14.8500 per share, resulting in an initial carrying value of $3,682,800. No gain or loss was recognized on the issuance of the Company’s own common stock.
The Company evaluated the option to acquire additional AnorTech shares under ASC 815 and concluded that it is not a derivative because it does not meet the net settlement criterion. The option provides for gross physical settlement, is a privately negotiated and non-transferable bilateral instrument, and the underlying AnorTech shares are restricted and not readily convertible to cash. The option was determined to have a de minimis fair value at inception, and no amount was allocated to it.
The investment is classified as a non-current asset, as the 60-month lock-up legally prevents a sale within twelve months and the Company holds the interest for strategic purposes.
As of September 30, 2026, the carrying value of the investment was $3,682,800. Cumulative upward adjustments, downward adjustments, and impairment recognized with respect to the investment since acquisition were $0. During the three and nine months ended September 30, 2026, the Company recognized no impairment and no adjustments resulting from observable price changes. In performing its qualitative impairment assessment as of September 30, 2026, the Company considered the limited and sporadic trading in AnorTech’s shares and concluded that quoted prices in those inactive markets do not, on their own, constitute an indicator of impairment. See Note 10 - Stockholders’ Equity for the common shares issued as consideration.
NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses consist of professional fees. The accounts payable and accrued expenses as of September 30, 2026 and December 31, 2025 were $956,582 and $76,764, respectively, in the accompanying condensed consolidated balance sheet.
18

Table of Contents
NOTE 8 — NOTES PAYABLE
As of September 30, 2026 and December 31, 2025, the Company had no third-party notes payable outstanding.
During 2025 and 2024, the Company issued a series of convertible and non-convertible promissory notes, all of which were repaid, converted, or settled during the year ended December 31, 2025.
Austria Capital LLC Convertible Promissory Note
On December 4, 2024, the Company issued a convertible promissory note with a principal amount of $1,200,000. The note bore no interest and had an original issue discount of $200,000 and deferred financing costs of $73,000. The Company also issued 40,000 shares of common stock to the investor as an equity inducement, valued at $978,000. The note was convertible into common stock at $12.50 per share following stockholder approval. The note was fully settled during the year ended December 31, 2025 through a combination of conversion into common stock and cash payment. See Note 10.
Red Road Holdings Promissory Note
Between December 2024 and April 2025, the Company entered into three loan agreements with Red Road Holdings with aggregate principal of $447,573, including guaranteed interest of $47,953, together with original issue discounts of $55,120 and deferred financing costs of $19,500. All three loans were repaid in full during the year ended December 31, 2025.
3i LP Institutional Investor Securities Purchase Agreement
On January 23, 2025, the Company entered into a Securities Purchase Agreement with an institutional investor providing for two senior convertible promissory notes with aggregate principal of $2,173,914, bearing interest at 7% per annum with an 8% original issue discount, together with two warrants to purchase up to an aggregate of 80,000 shares of common stock at an exercise price of $25.00 per share. The notes were convertible into common stock at $12.50 per share, subject to ownership limitations and certain adjustments, and were fully converted or repaid during the year ended December 31, 2025.
For the nine months ended September 30, 2025, the Company recognized interest expense of $3,491,961 in connection with these notes. No interest expense was recognized with respect to these notes during the three or nine months ended September 30, 2026.
NOTE 9 — RELATED PARTIES
On October 24, 2024, Dr. Joseph Sinkule and the Company entered into an Employment Agreement for a term of three years in connection with his appointment as the Company’s Chief Executive Officer. Pursuant to the Employment Agreement, Dr. Sinkule will receive an annual base salary of $360,000 and an initial equity award of 20,000 options pursuant to the Company’s 2023 Incentive Plan vesting immediately. The options are valid for a period of three (3) years and have an exercise price equal to the closing price of the Company’s common stock on October 24, 2024. In addition, Dr. Sinkule will be eligible to participate in the Company’s annual bonus program for executives.
On August 15, 2024, Mr. Jeffrey LeBlanc and the Company entered into an Employment Agreement for a term of three years in connection with his appointment as the Company’s Chief Financial Officer. Pursuant to the Employment Agreement, Mr. LeBlanc will receive an annual base salary of $325,000 and an initial equity award of shares of the Company’s common stock of 2,000 shares and an additional equity award of 8,000 shares of the Company’s common stock, with 4,000 of such shares vesting on the first anniversary of the agreement and 4,000 of such shares vesting on the second anniversary of the agreement. In addition, Mr. LeBlanc will be eligible to participate in the Company’s annual bonus program for executives.
In connection with the March 2026 acquisition of Greenland Mines Corp., the Company assumed approximately $298,000 of notes payable to related parties, which consist of unsecured promissory notes issued to multiple investors in connection with private placement transactions. Under these arrangements, investors subscribed to purchase units that included both a promissory note and common equity of the Company. These promissory notes generally bear interest at low stated rates (e.g., approximately 2%) and are payable upon the earlier of the Company obtaining specified financing proceeds or a stated maturity date (generally extending into 2027). The notes are unsecured and may be prepaid by the Company without penalty. As of September 30, 2026, these notes had been paid or net settled, and no balance of these notes was outstanding, and the Company recognized interest expense of approximately $4,950 and $11,453 during the three and nine months ended September 30, 2026, respectively.
19

Table of Contents

On March 1, 2026, Greenland Mines Corp., the Company's wholly owned subsidiary, entered into an Executive Employment Agreement with Mr. Bo Moller Stensgaard in connection with his appointment as head of the subsidiary. Effective May 14, 2026, the agreement was amended to provide a one-time sign-on equity award in the form of a fully-vested grant valued at $83,333. On June 30, 2026, the Company issued 6,428 shares of its common stock in settlement of the equity award. The Company recognized share-based compensation expense of $83,333 during the three months ended June 30, 2026, which are the same amounts as for the six and nine months ended September 30, 2026; no expense related to the sign-on award was recognized in the three months ended September 30, 2026.

Neo Performance Materials Inc. (“Neo Performance Materials”) was a stockholder of NNSR Holdings Inc., the sole stockholder of Neo North Star Resources, Inc. and received a portion of the consideration paid in the Sarfartoq Acquisition described in Note 3. Neo Performance Materials became a strategic shareholder of the Company in connection with the Sarfartoq Acquisition and retains offtake rights for up to 60% of future ore or mineral concentrate production from the Sarfartoq Project. The Company has no production, and no amounts were recorded under the offtake arrangement as of or for the periods ended September 30, 2026.

NOTE 10 — STOCKHOLDERS’ EQUITY
Equity Incentive Plan
In connection with the Business Combination, the Company’s Board adopted, and the Company’s stockholders approved, the Equity Incentive Plan (“Equity Incentive Plan”). At a special meeting held on September 3, 2026, the Company’s stockholders approved an amendment to the Equity Incentive Plan to increase the number of shares of common stock available for issuance under it to 400,000 shares, as adjusted for the Reverse Stock Split, subject to certain conditions. Although the Company does not have a formal policy with respect to the grant of equity incentive awards to the Company’s executive officers, the Company believes that equity awards provide the Company’s executive officers with a strong link to the Company’s long-term performance, create an ownership culture and help to align the interests of the Company’s executives and the Company’s stockholders. In addition, the Company believes that equity awards with a time-based vesting feature promote executive retention because this feature provides incentives for the Company’s executive officers to remain in employment with the Company during the applicable vesting period. Accordingly, the Company’s board of directors periodically reviews the equity incentive compensation of the Company’s executive officers and from time to time may grant equity incentive awards to them.

During the nine months ended September 30, 2026, the Company granted 161,000 restricted shares under the Equity Incentive Plan at a share price of $21.00, resulting in recognized stock-based compensation expense of $3,381,000.
During the year ended December 31, 2025, the Company granted 3,600 stock options under the Equity Incentive Plan at a weighted average fair value of $19.00, resulting in recognized stock-based compensation expense of $68,760.
During the year ended December 31, 2025, the Company granted 8,174 shares at a share price of $67.00 under the Equity Incentive Plan, to a member of management, resulting in stock-based compensation expense of $547,646. Unamortized stock-based compensation related to these grants was $0 as of December 31, 2025.
Non-Equity Incentive Plan Shares Issuances
During the nine months ended September 30, 2026, the Company granted 20,000 restricted shares at a share price of $21.00, unrelated to the Equity Incentive Plan, resulting in recognized stock-based compensation expense of $412,600. In addition, the Company modified previously issued, fully vested 12,000 stock options into 12,000 restricted shares, resulting in incremental recognized share-based compensation expense of $10,560.
During the nine months ended September 30, 2026, the Company issued 6,428 fully vested shares of common stock to the President of its wholly owned subsidiary as a sign-on award, resulting in recognized stock-based compensation expense of $83,333. See Note 9 – Related Parties for further information.
On February 14, 2026, the Company granted 20,000 shares of common stock to a consultant for services, fully vested upon grant, unrelated to the Equity Incentive Plan, resulting in recognized share-based compensation expense of $216,000.
On February 19, 2026, the Company granted 50,000 shares of common stock to a consultant, which were fully vested upon grant, unrelated to the Equity Incentive Plan, resulting in recognized share-based compensation expense of $589,500.
20

Table of Contents
During the year ended December 31, 2025, the Company granted 20,000 shares at a share price of $26.00, unrelated to the Equity Incentive Plan, related to a consulting agreement, resulting in professional fees of $516,000. Unamortized expenses related to these grants were $0 as of December 31, 2025. These shares were issued on January 2, 2026.
During the year ended December 31, 2024, the Company granted 65,709 shares and options, unrelated to the Equity Incentive Plan, at a weighted average fair value of $46.00, resulting in amortized stock-based compensation expense of $2,279,573. Stock-based compensation related to these awards totaled $713,375 during the year ended December 31, 2025. Unamortized stock-based compensation related to these grants was $69,375 as of December 31, 2025.
Private Placement
On March 2, 2026, the Company closed and completed the private placement (the “Financing”) contemplated by that certain Securities Purchase Agreement, dated February 19, 2026, by and among the Company and the purchasers named therein (the “Purchasers”).
At the closing of the Offering, the Company issued to the Purchasers an aggregate of 691,039 shares of the Company’s common stock and warrants to purchase up to an aggregate of 691,039 shares of Common Stock (the “Warrants”). The sale of the securities resulted in aggregate gross proceeds to the Company of approximately $7,750,000.
June 2026 Private Placement

On June 15, 2026, the Company entered into a Securities Purchase Agreement with three investors and, at a closing on June 18, 2026, issued 300,000 shares of common stock at $12.50 per share for gross proceeds of $3,750,000. The statement of changes in stockholders’ equity presents 306,016 shares for this issuance, which is the 300,000 shares issued plus 6,016 shares allocated to it from the round-up of fractional shares in the August 24, 2026 reverse stock split (see Note 2 and the Reverse Stock Split section of this note). No warrants were issued and there were no placement agent costs. The Company intends to use the proceeds for working capital and general corporate purposes.
AnorTech Share Exchange
On June 22, 2026, the Company issued 248,000 shares of its common stock to AnorTech Inc. in exchange for common shares representing approximately 9.9% of AnorTech, recorded as an investment of $3,682,800. No day-one gain or loss was recognized on the issuance of the Company’s own shares. See Note 6 – Investment in Equity Securities for further information.
Warrants
During February 2026, the Company entered into a consulting agreement under which it issued 50,000 shares of restricted common stock and 50,000 common stock purchase warrants to a third-party consultant in exchange for business development and advisory services. The equity instruments issued for services were accounted for in accordance with ASC 718 and measured at their grant date fair value. The associated expense is recognized in general and administrative expenses as the services are rendered (or upon vesting, if immediately vested). The warrants were determined to be equity-classified instruments recognized at fair value on the date of issuance.
Warrant Exercises
During the nine months ended September 30, 2026, other than the exercises described below, holders of common stock purchase warrants exercised 10 warrants at an exercise price of $174.50 per share, and the Company issued 10 shares of common stock for aggregate proceeds of $1,745. The exercised warrants were equity-classified.

Amendment and Exercise of Private Placement and Consulting Warrants

On September 21, 2026, the Company reduced the exercise price of the warrants issued in the February 2026 private placement and the warrants issued under the February 2026 consulting agreement to $5.00 per share, to give the holders an incentive to exercise. On September 21 and 22, 2026, holders exercised warrants for 741,039 shares of common stock, resulting in total proceeds to the Company of $3,705,195.

The Private Placement Warrants were classified as liabilities and measured at fair value through earnings. The Company remeasured the warrants exercised to their fair value of $6,323,022 at the exercise date, September 22, 2026, and recognized a loss of $513,612 in the change in fair value of warrant liabilities, compared with a carrying value of $5,809,409 at June 30, 2026. Upon exercise, the Company reclassified the liability to equity and recorded the liability and
21

Table of Contents
the cash proceeds of $3,455,195 in common stock at par value ($69) and additional paid-in capital ($9,778,147). See Note 2 for the measurement.

The 50,000 warrants issued under the February 2026 consulting agreement are classified in equity under ASC 718. The Company accounted for the reduction in exercise price as a modification. The incremental fair value, which is the excess of the fair value of the modified warrants over the fair value of the original warrants immediately before the modification on September 21, 2026, is estimated at approximately $18,500 and is recognized as stock-based compensation expense. On exercise on September 22, 2026, the Company received $250,000 and issued 50,000 shares.

August 2026 Registered Direct Offering

On August 27, 2026, the Company closed a registered direct offering under its shelf registration statement on Form S-3 (File No. 333-288533) of 1,632,783 shares of common stock at $5.00 per share and 2,367,217 pre-funded warrants at $4.9999 per pre-funded warrant, for aggregate gross proceeds of $19,999,763 before offering costs. A.G.P./Alliance Global Partners (“A.G.P.”) acted as exclusive placement agent on a reasonable best-efforts basis. The Company paid A.G.P. a cash fee of 7.0% of gross proceeds ($1,399,983) and a non-accountable expense allowance of $50,000, and reimbursed $65,000 of legal expenses. These costs, $1,514,983 in total, were recorded as a reduction of additional paid-in capital, and net proceeds were $18,484,780. Net proceeds of $18,485,017 reported in the statements of cash flows and changes in stockholders’ equity include $237 received on the exercise of the pre-funded warrants.

Each pre-funded warrant was immediately exercisable for one share of common stock at an exercise price of $0.0001 per share, has no expiration date, and is subject to a beneficial ownership limitation of 4.99% (9.99% at the holder’s election). The Company evaluated the pre-funded warrants under ASC 480-10-25 and ASC 815-40 and classified them in permanent equity, so they are not remeasured. Because the exercise price is nominal, the shares issuable on exercise are included in basic and diluted weighted-average shares from August 27, 2026 (ASC 260-10-45-13). All 2,367,217 pre-funded warrants were exercised by September 28, 2026. Continental Stock Transfer & Trust Company (“Continental”) issued 2,366,947 of the underlying shares through September 28, 2026. The remaining 270 shares, for which the exercise price had been paid, were issuable at September 30, 2026 and were issued on October 15, 2026. These 270 shares are included in the shares issued and outstanding at September 30, 2026 in the condensed consolidated balance sheet and statement of changes in stockholders’ equity. No pre-funded warrants were outstanding at September 30, 2026.

September 2026 Registered Direct Offerings

On September 23, 2026, the Company entered into securities purchase agreements with two institutional investors for a registered direct offering of 3,200,000 shares of common stock, including 1,434,580 shares issued on exercise of pre-funded warrants, at $12.00 per share, for gross proceeds of $38,400,000. On September 28, 2026, the Company entered into similar agreements with the same investors for 1,320,000 shares of common stock at $13.00 per share, for gross proceeds of $17,160,000. The shares were issued on the closing dates, and the Company received the proceeds between September 25 and September 30, 2026. Together the two offerings raised gross proceeds of $55,560,000 before offering costs.

Modification of Previously Issued Financing Warrants
During the year ended December 31, 2025, the Company reduced the strike price on certain of its issued warrants to induce exercise of the warrants, reducing the exercise price from $174.50 to $67.50 for certain outstanding warrants. The warrants were subsequently exercised (during the year ended December 31, 2025) as a result of the modification. In accordance with ASC paragraphs 815-40-35-16 through 17, the Company determined that the effect of the modification, which was calculated as $1,530,910, should be recognized as an equity issuance cost. As a result, the Company recognized a deferred offering cost with a corresponding increase to additional paid in capital. Further, upon exercise of the warrants, the Company, in accordance with SAB Topic 5.A, charged the deferred offering costs against the gross proceeds of the offering (i.e. a $1,530,910 reduction to additional paid in capital). During the year ended December 31, 2025, holders of common stock warrants exercised a total of 0.2 million warrants for gross proceeds of $11.4 million.
Austria Note Conversion
During the three months ended September 30, 2025, $650,000 of principal related to the Austria Capital LLC Convertible Promissory Note was converted into 52,000 shares of common stock at a conversion price of $12.50. The remainder of the note in the amount of $550,000 was settled in cash. Therefore, the Company de-recognized the remaining unamortized original issue discount of $85,554 and deferred financing costs of $438,471, which were recognized in interest expense on the condensed consolidated statements of operations. During the year ended December 31, 2025, the Company issued 40,000 additional shares in connection with settlement of the note, resulting in interest expense of $1,178,000.
22

Table of Contents
3i Note Conversion
During the year ended December 31, 2025, $823,444 of principal and $57,641 of interest and make whole related to 3i convertible notes was converted into 108,269 shares of common stock at conversion prices ranging from $6.00 to $12.50.
Investor Share Purchase
On June 5, 2025, the Company entered into a securities purchase agreement with an accredited investor pursuant to Regulation D of the Securities Act of 1933, as amended. Under the terms of the agreement, the Company issued 125,000 shares of its common stock at a purchase price of $4.00 per share, for total gross proceeds of $500,000. The proceeds were allocated to common stock based upon their par value of the common stock and the remainder was recorded to additional paid in capital on the condensed consolidated balance sheets.
Preferred B Shares
On June 9, 2025, the Company conducted a private offering and issued 500 preferred B shares at $0.0001 par value per share for a total of $500,000. The 500 preferred shares are convertible into 125,000 common shares. During the year ended December 31, 2025, all 500 preferred B shares were converted into 125,000 common shares.
Preferred C Shares
On March 4, 2026, the Company purchased mineral exploration rights and exploratory licenses and issued 47,940 preferred C shares at $0.0001 par value per share for a total fair value of $47,940,000. Each of the 47,940 preferred shares has a conversion option to convert into approximately 851 common shares (42,554 common shares before the 1-for-50 reverse stock split described below) upon shareholder’s approval.
The Series C Preferred Shares issued in connection with the Greenland Mines transaction had the following rights and privileges:
•Prior to stockholder approval, the holders of the Series C Preferred Shares have no voting rights and are not entitled to vote on any matters submitted to stockholders;
•Following stockholder approval, each share shall vote together with the common stock on an as-converted basis;
•Prior to stockholder approval, the Series C Preferred Shares are not convertible into common stock; and
•Upon stockholder approval, each share is convertible into shares of common stock at a stated conversion ratio
Pursuant to the Agreement and Plan of Merger dated March 4, 2026, the Company issued 47,000 shares of Series C Preferred Stock to the stockholders of Greenland Mines as consideration for the transaction. 940 Series C shares were issued as a finder’s fee related to the transaction. These shares were issued in connection with the asset acquisition and were subject to stockholder approval for both conversion and voting rights. Prior to such approval, the shares are non-voting and non-convertible; upon approval, they become convertible into common stock and participate in voting on an as-converted basis.
The Company has classified the Series C Preferred Stock within permanent equity. This classification, in accordance with ASC 480, is appropriate as the shares are not redeemable, do not contain any obligations requiring the Company to transfer assets, and do not embody features that would require liability classification under applicable accounting guidance.
The conversion feature embedded in the Series C Preferred Stock was evaluated under ASC 815 to determine whether bifurcation as a derivative instrument was required. The Company concluded that bifurcation is not required, as the conversion option:
•Is indexed to the Company’s own stock based on a fixed conversion ratio;
•Does not include any contingent settlement provisions that would require net cash settlement; and
•Does not embody any features that are not clearly and closely related to the host equity instrument.
Accordingly, the conversion feature qualifies for the scope exception for equity-linked instruments and is not required to be separated from the host instrument.
23

Table of Contents
At a special meeting of stockholders held on September 3, 2026, the Company’s stockholders approved, for purposes of Nasdaq Listing Rule 5635, the issuance of up to 40,800,776 shares of common stock (as adjusted for the Reverse Stock Split) upon conversion of the Series C Preferred Stock issued as consideration for the acquisition of Greenland Mines Corp. On September 3, 2026, the Board of Directors and the holders of a majority in interest of the Series C Preferred Stock agreed to amend the certificate of designation to limit conversion into common stock until the earlier of (i) January 8, 2027 and (ii) the next trading day after the fifth consecutive trading day on which the Nasdaq closing price of the common stock is at least $15.00 per share. Neither condition had been met as of September 30, 2026, conversion of the Series C Preferred Stock had not occurred.

Preferred R Shares

On September 1, 2026, in connection with the Sarfartoq Acquisition described in Note 3, the Company issued 359,324 shares of Series R Convertible Preferred Stock, $0.0001 par value per share (the “Series R Preferred Stock”), with a fair value of $1,282,382, which is included in the consideration transferred. The Series R Preferred Stock is non-voting and, subject to stockholder approval, convertible into common stock on a one-for-one basis. Because stockholder approval had not been obtained as of September 30, 2026, the Series R Preferred Stock was not convertible. See Note 2. The Company has classified the Series R Preferred Stock within permanent equity.

Employee Awards
On March 1, 2026, Greenland Mines Corp., the Company’s wholly owned subsidiary, entered into an Executive Employment Agreement with Mr. Bo Moller Stensgaard in connection with his appointment as head of the subsidiary. Effective May 14, 2026, the agreement was amended to provide a fully-vested equity grant valued at $83,333. On June 30, 2026, the Company issued 6,428 shares of its common stock (321,377 shares before the 1-for-50 reverse stock split) in settlement of the equity award. The Company recognized share-based compensation expense of $83,333 during the three months ended June 30, 2026, which are the same amounts as for the six and nine months ended September 30, 2026; no expense related to the sign-on award was recognized in the three months ended September 30, 2026.

Meteora Agreement
On June 13, 2024, RWOD and the Company entered into a forward purchase agreement with (i) Meteora Capital Partners, LP (“MCP”), (ii) Meteora Select Trading Opportunities Master, LP (“MSTO”), and (iii) Meteora Strategic Capital, LLC (“MSC” and, collectively with MCP and MSTO, the “Seller”) (the “Forward Purchase Agreement”). Redwoods is the holder of the asset and Sponsor and is also a counterparty to the Company. Upon Closing of the merger on June 21, 2024 and on September 30, 2024, the value of the contract was $0 as the contract created no receivable or obligation for the Company. On September 19, 2024, the Company modified the settlement amount price of the contract to $100.00 and allowed the shares held with Meteora to be sold at Meteora’s sole discretion, with the reset price subject to weekly changes. During the quarter ending March 31, 2025, Meteora sold and terminated on behalf of the Company 2,000 shares at a reset price of $23.0500, for total proceeds to the Company in the amount of $46,100. On May 15, 2025, Meteora terminated an additional 11,004 shares at a reset price of $8.5850 for total proceeds of $94,472, thereby reducing the number of shares per the agreement to 200 shares remaining.
During September 2025, the Company entered into a second amendment (the “Second Amendment”) to the Forward Purchase Agreement with MCP which primarily (i) increased the maximum number of shares to 135,100 and (ii) modified the reset price to $500.00 subject to a reset on a weekly basis. In connection with the modification, which relates to the reverse merger, the Company issued 134,900 common shares under the arrangement to MCP. The Company recognized the common shares at par value in the amount of $14 on the consolidated balance sheets with a corresponding recording of additional paid-in capital. During the year ending December 31, 2025, Meteora sold and terminated on behalf of the Company 2,000 shares at a reset price of $23.0500, for total proceeds to Klotho in the amount of $46,100. During the three months ended March 31, 2026, Meteora sold and terminated on behalf of the Company 18,467 shares at a reset price of $11.7600 and 9,158 shares at a reset price of $21.3000, for total proceeds to Klotho in the amount of $412,329. The Forward Purchase Agreement entered the valuation date on September 18, 2026, and the Company recognized an expense of $306,304 for the remaining previously issued 107,475 common shares under the Forward Purchase Agreement.
At-the-Market Sales Agreement
On July 3, 2025, the Company entered into a sales agreement with A.G.P./Alliance Global Partners (“A.G.P.”) relating to the sale of newly issued shares of the Company’s common stock. In accordance with the terms of the sales agreement, the Company may offer and sell shares of its common stock having an aggregate offering amount of up to $50,000,000 from
24

Table of Contents
time to time through A.G.P., acting as the Company’s sales agent or principal. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes.
During the year ended December 31, 2025, the Company sold 44,139 shares at a weighted average price of $25.00 per share for gross proceeds of $1,112,745. During the six months ended June 30, 2026, the Company sold 197,802 shares of common stock under the sales agreement at a weighted average price of approximately $13.50 per share, for gross proceeds of approximately $2,661,148 (the $2,574,725 recorded in equity is net of the 3.25% sales agent’s commission.). The statement of changes in stockholders’ equity presents 201,768 shares for these sales, which is the 197,802 shares sold plus 3,966 shares allocated to them from the round-up of fractional shares in the August 24, 2026 reverse stock split (see Note 2 and the Reverse Stock Split section of this note). Effective July 4, 2026, the Company terminated the Sales Agreement. No termination penalties were incurred, and no shares remain available for sale under the Sales Agreement.
August 2026 At-the-Market Sales

In August 2026, the Company resumed sales of its common stock through A.G.P. under a sales agreement dated August 20, 2026 providing for sales of up to $50,000,000. On August 25, 2026, the Company sold 143,505 shares of common stock at approximately $9.68 per share for gross proceeds of $1,388,827. No other shares were sold under the agreement. On September 23, 2026, the Board of Directors approved the termination of the sales agreement, and the Company stated in a prospectus supplement filed the same day that the continuous offering had terminated and that no further shares would be sold.

Reverse Stock Split
On June 18, 2026, the Company’s stockholders approved a proposal granting the board authority to effect one or more reverse stock splits at a ratio between 1-for-2 and 1-for-50, with the aggregate of all such splits not to exceed 1-for-60, at any time on or before March 31, 2027. On August 24, 2026, the Company effected a 1-for-50 reverse stock split of its issued and outstanding common stock by filing a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation. The par value of $0.0001 per share and the 1,000,000,000 authorized shares of common stock were not changed. Immediately before the split, the Company had 158,850,637 shares outstanding; after the split, 3,177,094 shares were recorded at the transfer agent on August 24, 2026. Fractional shares held at the beneficial holder level were rounded up to the next whole share, and on September 1, 2026 the Company issued 63,627 additional shares for the round-up. The 63,708 round-up shares (81 recorded at the holder level on August 24, 2026 and 63,627 issued on September 1, 2026) have been allocated to the pre-split issuances presented, in proportion to the shares issued in each, so that common shares outstanding are presented as 3,240,721 at June 30, 2026 (3,177,013 before the allocation) and 1,479,826 at December 31, 2025. The share counts stated in the narrative descriptions of individual issuances in this note are the shares actually issued and do not include the allocation. Because the reverse stock split has been applied retroactively, the reduction in aggregate par value was reclassified from common stock to additional paid-in capital in each period presented ($15,561 at June 30, 2026 and $7,106 at December 31, 2025), with no effect on total stockholders’ equity. The exercise prices of outstanding warrants and the number of shares issuable on exercise were adjusted in proportion to the split under their anti-dilution provisions, which the Company did not account for as modifications. As described in Note 2, all share and per-share amounts in these condensed consolidated financial statements and notes, including the share data in the condensed consolidated statements of changes in stockholders’ equity, weighted-average shares and loss per share, have been retroactively adjusted to reflect the reverse stock split for all periods presented.

NOTE 11 — COMMITMENTS AND CONTINGENCIES
From time to time, the Company is subject to various legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. Although the outcome of the various legal proceedings and claims cannot be predicted with certainty, management does not believe that any of these proceedings or other claims will have a material effect on the Company’s business, financial condition, results of operations or cash flows.
Purchase Commitments
In the ordinary course of business, the Company enters into agreements with vendors and service providers, including in connection with the exploration and evaluation of the Skaergaard Project. These arrangements are generally cancelable and do not contain material non-cancelable purchase obligations. As of September 30, 2026, the Company did not have any material non-cancelable purchase commitments that would require separate accrual or disclosure under applicable accounting guidance.

NOTE 12 — SEGMENT INFORMATION
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an
25

Table of Contents
individual segment and in assessing performance. Historically, the Company operated as a single reporting segment, focused on developing gene therapy for neurodegenerative diseases. However, as a result of the asset acquisition that occurred during March of 2026, the Company now reports under two reportable segments: Biotech and Mining. On September 1, 2026, the Company completed the acquisition of the Sarfartoq Nd-Pr rare earth element project (see Note 3, Acquisitions). The Sarfartoq Project is included within the Mining segment, alongside Skaergaard, which was the Company’s only mining project before that date, and the Company continues to report under two reportable segments: Biotech and Mining. Because the Mining segment was established in March 2026 and the Sarfartoq Project was added to it on September 1, 2026, comparative segment information for the three and nine months ended September 30, 2025 reflects only the Biotech segment.

The Company has two reportable segments: (i) biotechnology operations focused on research and development activities, and (ii) mineral resource development and exploration, which includes the Skaergaard Project and the Sarfartoq Project. The Company’s measure of segment profit or loss for each reportable segment is net loss. The Chief Operating Decision Maker (“CODM”), identified as the Company’s Chief Executive Officer, evaluates performance and allocates resources between the biotechnology and mining segments.

The CODM reviews financial information for each segment, as well as on a consolidated basis, to assess performance, forecast future operating results, and determine the appropriate allocation of resources consistent with the Company’s overall strategic objectives. Operating expenses are reviewed for each segment to monitor budget-to-actual performance. In addition, the CODM utilizes net loss metrics in competitive benchmarking analyses against peer companies within each respective industry, and this analysis, together with budget monitoring, is used in evaluating segment performance and resource allocation decisions.
Mining amounts include the Sarfartoq Project only for the period from September 1, 2026 (acquisition date) through September 30, 2026. Total is the sum of Biotech and Mining. Amounts are rounded to whole dollars.

The following table reflects segment profit or loss, significant expense categories and other segment items regularly provided to the CODM when managing the Company’s reportable segments. A reconciliation to the consolidated net loss for the three and nine months ended September 30, 2026 and 2025 is included at the bottom of the tables below.
For the Three Months Ended September 30,
20262025
BiotechMiningTotalBiotechTotal
Significant segment expenses
General and administrative(1)
$244,621 $1,223,973 $1,468,594 $868,830 $868,830 
Research and development409,521 - 409,521 273,305 273,305 
Exploration and evaluation- 6,304,794 6,304,794 - - 
Professional fees798,435 3,431,322 4,229,757 711,169 711,169 
Interest expense (income)4,950 - 4,950 1,177,999 1,177,999 
Other segment items233,260 175,541 408,801 (56,271)(56,271)
Total operating and segment expenses$1,690,787 $11,135,630 $12,826,417 $2,975,032 $2,975,032 
Reconciliation of net loss
Change in fair value of warrant liabilities$815,660 (79,447)
Consolidated net loss$13,642,077 $2,895,585 
26

Table of Contents
For the Nine Months Ended September 30,
20262025
BiotechMiningTotalBiotechTotal
Significant segment expenses
General and administrative(1)
$1,571,996 $6,686,869 $8,258,865 $2,213,254 $2,213,254 
Research and development1,131,328 - 1,131,328 747,435 747,435 
Exploration and evaluation- 6,865,824 6,865,824 - - 
Professional fees2,091,256 9,069,624 11,160,880 2,372,435 2,372,435 
Interest expense (income)11,453 - 11,453 3,491,961 3,491,961 
Impairment expense2,045,253 - 2,045,253 - - 
Other segment items240,547 155,410 395,957 (79,603)(79,603)
Total operating and segment expenses$7,091,833 $22,777,727 $29,869,560 $8,745,482 $8,745,482 
Reconciliation of net loss
Change in fair value of warrant liabilities1,314,780 28,514 
Consolidated net loss$31,184,340 $8,773,996 
(1)Excludes impairment of licenses and patents; includes share based compensation expense
Segment assets for Mining comprise mineral rights and exploration licenses of $73.9 million as of September 30, 2026, of which $48.4 million relates to Skaergaard, acquired in March 2026, and $25.4 million to Sarfartoq, acquired September 1, 2026. The Sarfartoq amount is the total acquisition cost described in Note 3. There were no Mining segment assets as of December 31, 2025. Segment assets for Biotech comprise intangible assets of $0.3 million and $2.3 million as of September 30, 2026 and December 31, 2025, respectively. Property, plant and equipment of $440,457 and the investment in equity securities of $3,682,800 are not allocated to a segment.

NOTE 13 — SUBSEQUENT EVENTS
The Company has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date these condensed consolidated financial statements were issued, and has determined that the following subsequent events exist:
Exercise of Option to Acquire Additional AnorTech Shares

On November 6, 2026, the Company purchased, pursuant to an option contained in the Share Exchange Agreement with AnorTech, a total of 25,168,669 additional common shares of AnorTech at a deemed price of C$0.30 per share, or C$7,550,601 in the aggregate, payable in 1,133,268 shares of the Company’s common stock, based on the 10-day volume-weighted average trading price on Nasdaq. Following closing, the Company holds 45,127,172 AnorTech common shares, approximately 19.9% of AnorTech’s outstanding common shares, compared with 19,958,503 shares, or approximately 9.9%, at September 30, 2026. AnorTech holds 1,433,302 shares of the Company’s common stock, approximately 9.7% of the 14,819,209 shares outstanding as of November 12, 2026, and 17,966 shares of non-voting Series R convertible preferred stock. The additional AnorTech shares are subject to a 60-month contractual lock-up, and the Company’s shares issued to AnorTech are subject to a contractual lock-up as to one-half for 12 months and one-half for 24 months.

The exercise and closing occurred after September 30, 2026 and did not affect the condensed consolidated financial statements as of or for the three and nine months ended September 30, 2026. It is a nonrecognized (Type II) subsequent event under ASC 855-10-25-3. At September 30, 2026, the option was not in-substance common stock under ASC 323-10-15-13 and 15-14 and was not included in assessing significant influence. The Company expects to record the additional shares at the fair value of the 1,133,268 shares issued, approximately US$4.0 million based on the November 5, 2026 closing price of $3.57 before any adjustment for the lock-up. That would increase the carrying amount of the investment from $3,682,800 to approximately $7.7 million before any impairment. Because ownership after closing is approximately 19.9%, close to the 20% presumption in ASC 323-10-15-8, the Company evaluated significant influence as of the closing date under ASC 323-10-15-6. The Company has no board representation, does not participate in AnorTech’s policy-making, has no interchange of managerial personnel or technological dependency, and to its knowledge none of AnorTech’s other shareholders is a related party. It concluded that it does not have significant influence and that AnorTech
27

Table of Contents
is not a related party. The investment, including the additional shares, will continue to be accounted for under the measurement alternative in ASC 321-10-35-2, and the Company will assess the combined investment for impairment.

Subscription for Battery Mineral Resources Corp. Shares

On November 6, 2026, the Company entered into a subscription agreement with Battery Mineral Resources Corp. (“BMR”) to purchase 7,000,000 BMR common shares at C$0.20 per share, for an aggregate purchase price of C$1,400,000 (approximately US$1.0 million), in a private placement. The Company made the investment to obtain exposure to additional critical minerals projects. BMR has approximately 417.9 million common shares outstanding, so the 7,000,000 shares represent approximately 1.7% of its common shares, and BMR has no relationship with the Company or its officers or directors. BMR accepted the subscription on November 6, 2026. The Company paid the purchase price on November 6, 2026. Issuance of the shares is subject to approval by the TSX Venture Exchange and other regulatory approvals. If closing has not occurred within 60 days after the Company delivers the purchase price, the Company may terminate the agreement and recover the amount paid without interest. The subscription was entered into after September 30, 2026 and did not affect the Company’s condensed consolidated financial statements as of or for the three and nine months ended September 30, 2026. It is a nonrecognized (Type II) subsequent event under ASC 855-10-25-3.

Share Repurchase Program

As of October 5, 2026, the Company’s Board of Directors, by unanimous written consent, authorized a share repurchase program, under which the Company may repurchase up to $20 million in aggregate purchase price, including brokerage fees and commissions, of its outstanding common stock from time to time through open-market transactions or other permissible methods, including pursuant to trading plans established under Rules 10b5-1 and 10b-18, where applicable. The timing and amount of any repurchases will depend on market conditions, the Company’s share price, liquidity requirements, project funding needs and other capital allocation considerations. The authorization does not obligate the Company to repurchase any particular amount of common stock and may be modified, suspended or discontinued at any time. The program has no expiration date and continues until the full $20 million has been used or the Board terminates it. Repurchases may be made only out of funds legally available under Delaware law, and repurchased shares may be held as treasury shares or retired. As of the date of this Quarterly Report, the Company had not repurchased any shares under the program. Repurchases may be subject to the 1% U.S. federal excise tax on net stock repurchases, which the Company would record as part of the cost of the shares repurchased. The Company has not factored the program into its evaluation of its ability to continue as a going concern (Note 2). The authorization is a nonrecognized (Type II) subsequent event and did not affect the Company’s condensed consolidated financial statements as of or for the three and nine months ended September 30, 2026.

Planned Contribution of Biotech Segment Assets

The Company has publicly announced its intention to separate its Biotech segment from the Company during the fourth quarter of 2026. As of October 12, 2026, the Company’s Board of Directors authorized the contribution of its biotechnology-related assets and $5.5 million in cash to Mojo BioPharma, Inc. (“Mojo”), a privately held Delaware corporation, in exchange for shares of Mojo common stock equal to 10% of Mojo’s shares outstanding after closing, on a fully diluted, as-converted basis, and Mojo would assume certain biotechnology-related liabilities.

The transaction had not closed as of September 30, 2026 or as of the date of this Quarterly Report. Because the transaction had not closed as of September 30, 2026, it did not result in any recognition, measurement, or presentation impact in the Company’s condensed consolidated financial statements as of or for the three and nine months ended September 30, 2026. As of the date of this Quarterly Report, the Company had paid $1.0 million of the $5.5 million cash contribution to Mojo.

Management evaluated the potential transaction against the held-for-sale criteria in ASC 360-10-45-9 and the discontinued-operations criteria in ASC 205-20 as of September 30, 2026, and concluded that neither was met as of that date, based on, among other things, the absence of a definitive, board-approved agreement as of that date (the Board authorized the contribution to Mojo on October 12, 2026), the absence of an active program to market the underlying assets to unrelated buyers, and the fact that the anticipated closing was subsequent to the balance sheet date. This is a nonrecognized (Type II) subsequent event under ASC 855-10-25. The ultimate accounting for the transaction will depend on, among other things, whether the contributed licenses and contracts constitute a business under ASC 805-10-55; management currently expects the transaction, if completed as described, to be accounted for as a nonmonetary exchange of nonfinancial assets for a noncontrolling equity interest under ASC 610-20, though the deconsolidation guidance in ASC 810-10-40 may apply instead depending on that determination. The Company has not determined the fair value of the Mojo shares to be received or the carrying amount of the assets and liabilities to be contributed, and it cannot yet estimate the gain or loss, if any, that it will record on closing. See also Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations.
28

Table of Contents

Meteora Forward Purchase Agreement

On November 13, 2026, the Company terminated the FPA agreement with Meteora and will issue approximately 129,870 shares of common stock as final adjustment consideration.


29

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
References in this report (this “Quarterly Report”) to “we,” “us” or the “Company” refer to Greenland Mines Ltd. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report, including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual events, performance or results to differ materially from those anticipated in the forward-looking statements, please refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the “SEC”), and the Company’s subsequent filings with the SEC. The Company’s filings with the SEC can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview and Recent Developments
On March 4, 2026, we completed the acquisition of Greenland Mines Corp., resulting in a significant strategic transformation. Through the transaction, we acquired an indirect 80% interest in the Skaergaard Project, a large-scale mineral exploration asset located in southeast Greenland, and expanded our business to include mining operations. In connection with the transaction, on March 11, 2026, we changed our legal name from Klotho Neurosciences, Inc. to Greenland Mines Ltd, and our common stock and warrants began trading under the symbols “GRML” and “GRMLW” on the Nasdaq Capital Market effective March 12, 2026.
As a result of the mining-related acquisitions, we operate through two reportable segments: (i) Biotech and (ii) Mining. Our Mining segment holds two projects: Skaergaard, which focuses on the exploration and development of the Skaergaard Project, and Sarfartoq, established upon our September 1, 2026 acquisition of the Sarfartoq Nd-Pr rare earth element project, which focuses on the exploration and development of that project. This expansion represents a significant change in our business strategy and future capital allocation priorities.

Our Biotech segment is focused on the development of therapies for chronic and neurodegenerative diseases. Our biotechnology platform includes a gene therapy platform designed to deliver the “Klotho” protein for the treatment of neurodegenerative diseases, with our lead program, KLTO-202, targeting amyotrophic lateral sclerosis (ALS). We have not generated revenue from these programs, and our biotech activities consist principally of research and development and related licensing arrangements.
On May 20, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) to acquire Neo North Star Resources, Inc. (“Neo North Star”), the holder of the Sarfartoq Rare Earth Element Project, a neodymium-praseodymium (“Nd-Pr”) rare earth element exploration property in southwest Greenland (the “Sarfartoq Project”), from its stockholders. On September 1, 2026, the Company entered into an Amendment to the Merger Agreement (this “Amendment”) by and among Company, Greenland Rare Earths Corp., a Delaware corporation (“Merger Sub”), Neo North Star, the stockholders of Neo North Star, and Lazaros Nikeas, as the representative of the stockholders of Neo North Star. The Amendment (a) substituted a new parent entity, NNSR Holdings Inc., a Delaware corporation and sole stockholder of Neo North Star for Neo North Star under the Merger Agreement and (b) fixed the equity consideration payable by the Company under the Merger Agreement as 1,040,676 newly issued shares of Company’s common stock and 359,324 newly issued shares of a newly designated series of the Company’s preferred stock. On September 1, 2026, the Company
30

Table of Contents
completed the acquisition (the “Sarfartoq Acquisition”). For accounting purposes, we measured the equity consideration at its fair value on the acquisition date of $5.4 million, Total consideration transferred was therefore $25.3 million, and the mineral property cost basis was $25.4 million including transaction costs. The offtake rights for up to 60% of future Sarfartoq ore or mineral concentrate production remain with NPM Silmet OÜ, a subsidiary of Neo Performance Materials Inc., under an agreement dated April 20, 2023. See Note 3, Acquisitions, to our condensed consolidated financial statements.

On June 22, 2026, we completed a share exchange with AnorTech Inc., issuing 248,000 shares of our common stock in exchange for common shares representing approximately 9.9% of AnorTech’s outstanding common stock, together with an option to acquire additional AnorTech shares. We recorded the investment at $3,682,800. See Note 6 to our condensed consolidated financial statements.
During the nine months ended September 30, 2026, we advanced exploration and evaluation activities at the Skaergaard Project, including the preparation of a mineral resource estimate under SEC Regulation S-K Subpart 1300 standards (effective July 3, 2026), and our 2026 field program, which we completed in October 2026. Following the September 1, 2026 acquisition, we completed an early-stage geological mapping and sampling program at the Sarfartoq Project in September 2026; as of September 24, 2026, we had not received assay results from that program. A technical report summary for the Sarfartoq Project prepared under SEC Regulation S-K Subpart 1300, effective July 31, 2026, reports estimated Indicated and Inferred mineral resources. Our mineral properties are non-producing and have not been demonstrated to contain mineral reserves as defined under Regulation S-K Subpart 1300, and we expense exploration and evaluation costs as incurred.

Mineral Properties

Skaergaard Project

The Skaergaard Project is an undeveloped palladium, gold and platinum deposit in southeast Greenland. Through our March 2026 acquisition of Greenland Mines Corp., we hold an 80% indirect interest in the project. The project is in the exploration stage. The project is held under three exploration licenses: MEL 2012-25 and MEL 2021-10, which expire on December 31, 2026, and MEL 2007-01, which expires on December 31, 2027. We plan to apply to renew each of them. Our initial S-K 1300 Technical Report Summary, effective July 3, 2026, reports estimated Indicated Mineral Resources of 153.6 million tons at 3.04 g/t palladium equivalent and Inferred Mineral Resources of 177.5 million tonnes/tons at 3.07 g/t palladium equivalent. Mineral resources are not mineral reserves and do not have demonstrated economic viability, and we have not established mineral reserves at the project. In 2026 we completed a field program that included 4,480 meters of diamond drilling in 17 holes and the extraction of more than 104 tons of bulk material for metallurgical testwork; assay results and quality assurance review were pending when we announced the completion of the program on October 1, 2026. The carrying value of the project’s mineral rights and exploration licenses was $48,416,474 at September 30, 2026, and exploration and evaluation expense for the project was $6,224,553 for the three months and $6,785,583 for the nine months ended September 30, 2026.

Sarfartoq Project

The Sarfartoq Project is a neodymium-praseodymium (Nd-Pr) rare earth element exploration property in southwest Greenland. We acquired it on September 1, 2026 through our acquisition of NNSR Holdings Inc., the sole stockholder of Neo North Star Resources, Inc., the holder of the project (see Note 3). Neo Performance Materials Inc., a related party, retains offtake rights for up to 60% of future production from the project. The project is held under exploration License No. 2020-32, and on August 19, 2026 the Government of Greenland approved the indirect transfer of the license to the Company. Our S-K 1300 Technical Report Summary, effective July 31, 2026, reports estimated Indicated Mineral Resources of 6.9 million tons at 1.60% total rare earth oxide (“TREO”) and Inferred Mineral Resources of 5.3 million tons at 0.96% TREO. Mineral resources are not mineral reserves and do not have demonstrated economic viability, and we have not established mineral reserves at the project. In September 2026 we completed an early-stage geological mapping and sampling program at the project; as of September 24, 2026, we had not received assay results. The carrying value of the project’s mineral rights and exploration licenses was $25,438,830 at September 30, 2026, and exploration and evaluation expense for the project was $80,241 for the period from September 1, 2026 to September 30, 2026.

On August 24, 2026, following stockholder approval on June 18, 2026 of authority for our Board of Directors to effect one or more reverse stock splits, we effected a 1-for-50 reverse stock split of our common stock in an effort to regain compliance with Nasdaq’s minimum bid price requirement. We regained compliance on September 2, 2026. At a special meeting of stockholders held on September 3, 2026, our stockholders approved the issuance of up to 40,800,776 shares of common stock upon conversion of our Series C Preferred Stock, the issuance of up to 691,039 shares of common stock upon exercise of the private placement warrants, and an increase in the shares available under our Equity Incentive Plan to 400,000 shares, each as adjusted for the reverse stock split. See “Liquidity and Capital Resources.” All share and per-share
31

Table of Contents
amounts in this Quarterly Report, including amounts for periods before August 24, 2026, have been retroactively adjusted to reflect the reverse stock split.

In August 2026, we sold 143,505 shares under our at-the-market sales agreement for gross proceeds of $1.39 million and closed a registered direct offering of common stock and pre-funded warrants for gross proceeds of $19,999,763. In September 2026, we raised gross proceeds of $55.56 million in two registered direct offerings and received $3.7 million on the exercise of warrants at a reduced exercise price of $5.00 per share. See Notes 10 and 13.

On September 25, 2026, our common stock began trading on the Frankfurt Stock Exchange under the symbol “HK6,” in addition to our Nasdaq listing under “GRML.” No new shares were issued in connection with the Frankfurt listing. There were several changes to the composition of our Board of Directors during the quarter. In September 2026, directors Riad El-Dada, Shalom Hirschman, and Jon McGarity resigned; in the same month, we added Jason Hawkins, Blair Jordan, and Peter Love to our Board of Directors.

After September 30, 2026, we announced the completion of the 2026 field program at the Skaergaard Project (October 1, 2026), which included 4,480 meters of diamond drilling in 17 holes, more than 104 tons of bulk material for metallurgical testwork and a metallurgical and processing program with GTK Mintec. Assay results and quality assurance review were pending. We also reported that gallium and vanadium are potential by-products of Skaergaard mineralization, although no recovery or economic value has been established for them. As of October 5, 2026, our Board of Directors authorized a $20 million share repurchase program, and on October 6, 2026 we announced the program and our capital allocation priorities, which are drilling, technical studies, metallurgy, environmental programs and permitting at Sarfartoq and Skaergaard, and the evaluation of strategic investments and partnerships. In October 2026, our Board authorized the contribution of our biotechnology-related assets and $5.5 million in cash to a private company in exchange for a 10% equity interest. On November 6, 2026, the Company purchased, pursuant to an option contained in the Share Exchange Agreement with AnorTech, a total of 25,168,669 additional common shares of AnorTech at a deemed price of C$0.30 per share, or C$7,550,601 in the aggregate, payable in 1,133,268 shares of the Company’s common stock. On November 6, 2026, we agreed to subscribe for 7,000,000 common shares of Battery Mineral Resources Corp. for C$1,400,000 (approximately US$1.0 million), subject to TSX Venture Exchange approval. See Note 13.

On June 23, 2026, our Audit Committee dismissed BCRG Group as our independent registered public accounting firm and approved the appointment of Simon & Edward LLP (“Simon & Edward”), following Simon & Edward’s acquisition of BCRG’s attest business. BCRG’s audit reports on our financial statements for the years ended December 31, 2025 and 2024 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, other than the going-concern explanatory paragraph previously disclosed. During the years ended December 31, 2025 and 2024, and through June 23, 2026, there were no disagreements with BCRG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, and no reportable events, other than the material weaknesses in internal control over financial reporting previously disclosed in our Annual Report on Form 10-K. We did not consult with Simon & Edward on any accounting or auditing matters prior to its engagement.
Results of Operations
We have not generated any operating revenues to date. To date, the Company’s operations have consisted of acquiring our licensed platforms and patents, and planning for the Business Combination. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as our expenses associated with planning our research and clinical testing operations.
Results of Operations for the Three Months Ended September 30, 2026 Compared to the Three Months Ended September 30, 2025
Revenues
The Company had no revenue for the three months ended September 30, 2026 and 2025.
Operating Expenses
Our operating expenses for the three months ended September 30, 2026 were approximately $12.4 million compared to approximately $1.9 million for the three months ended September 30, 2025, an increase of approximately $10.6 million, or 569.8%. The increase was primarily attributable to exploration and evaluation expenses related to our 2026 field program, which we did not incur in the prior-year period; higher professional fees, principally marketing and investor relations expenses; and higher general and administrative expenses. .
32

Table of Contents

Professional fees increased by approximately $3.5 million, or 494.8%, to approximately $4.2 million for the three months ended September 30, 2026 from approximately $0.7 million for the three months ended September 30, 2025. The increase was primarily attributable to:
•approximately $3.1 million of marketing, investor awareness and investor relations expenses, which we did not incur in the prior-year period;
•approximately $0.2 million of additional legal, accounting, consulting and advisory costs associated with public company reporting requirements, regulatory compliance matters, capital markets activities and strategic initiatives; and
•approximately $0.2 million of technical consulting and mining-related professional services incurred following the acquisition of Greenland Mines Corp. and in connection with evaluating and advancing the Company’s mineral exploration activities.
General and administrative expenses increased by approximately $0.6 million, or 69.0%, to approximately $1.5 million for the three months ended September 30, 2026 from approximately $0.9 million for the three months ended September 30, 2025. The increase was primarily attributable to increases in expenses related to payroll and personnel, insurance, investor relations, and other corporate infrastructure. The increase also reflects higher share-based compensation expense associated with equity awards granted to employees, officers, directors, and consultants, as well as recurring administrative costs such as subscriptions, technology services, and office-related expenses. Share-based compensation included in general and administrative expenses was $907,375 for the three months ended September 30, 2026 compared to $637,426 for the three months ended September 30, 2025.

Research and development expenses increased by approximately $136,216, or 50%, to approximately $409,521 for the three months ended September 30, 2026 from approximately $273,305 for the three months ended September 30, 2025. The increase was primarily attributable to continued spending on the Company’s biotechnology programs, including scientific development efforts, third-party research activities and intellectual property development initiatives.
The research and development expenses by program for the three months ended September 30, 2026 and 2025 are as follows:
ProgramThree Months Ended
September 30,
2026
Three Months Ended
September 30,
2025
KLTO-101 and KLTO-202$243,227 $273,305 
Klotho Clock88,951 - 
New Development30,000 - 
Other47,343 - 
Total$409,521 $273,305 
Exploration and evaluation expenses were approximately $6,304,794 for the three months ended September 30, 2026 compared to $0 for the three months ended September 30, 2025. We had no exploration and evaluation expenses in the prior-year period because we had no mineral exploration operations before our March 4, 2026 acquisition of Greenland Mines Corp. and our September 1, 2026 acquisition of the Sarfartoq Project. The 2026 expenses consisted of $6,224,553 for the Skaergaard Project, related principally to our 2026 field program, which we completed on October 1, 2026 and which included 4,480 meters of diamond drilling in 17 holes, and $80,241 for the Sarfartoq Project from September 1, 2026. By nature, the expenses consisted principally of vessel and aircraft charter costs ($2.0 million), contracted drilling services and supplies ($1.7 million), professional and technical services, including geophysical, geotechnical and environmental work and contract field personnel ($1.3 million), and helicopter support and crew travel ($0.8 million), with the remainder consisting of freight and shipping, fuel, equipment rental, and assay and sample analysis. Expenses in the third quarter were higher than the $561,030 recorded in the six months ended June 30, 2026 because the field program was carried out principally during the third quarter.
33

Table of Contents
The exploration and evaluation expenses by category were as follows:
CategoryThree months ended September 30,Nine months ended September 30,
Drilling Costs and Supplies$1,689,317 $1,887,097 
Camp and Logistics808,659 988,309 
Assay and Sample Analysis18,328 22,253 
Equipment Rental - Mining128,444 129,539 
Professional and Technical Services1,323,309 1,501,889 
Freight and Shipping194,712 194,712 
Charter Expense1,998,614 1,998,614 
Fuel143,411 143,411 
Total Exploration and Evaluation Expense$6,304,794 $6,865,824 
Drilling costs and supplies consisted primarily of contracted diamond drilling services for the 2026 field program, together with core storage, explosives and geological supplies. Camp and logistics costs consisted primarily of helicopter support for the field program, together with crew travel, camp supplies and field communications equipment. Assay and sample analysis costs consisted of certified reference materials, blanks and sample packaging used in the Company’s quality assurance program; laboratory assay results from the 2026 program were pending when the Company announced the completion of the program on October 1, 2026. Equipment rental costs related to drilling and blasting equipment, with operators, and geophysical survey equipment. Professional and technical services consisted of contract geologists and field personnel, drill planning and geotechnical support, environmental baseline studies and geophysical field services. Charter expense consisted of vessel charters, including voyage costs, and chartered aircraft used to move personnel, cargo and equipment to and from the project areas. Freight and shipping costs consisted of export clearance, air and sea freight and transport of equipment and samples. Fuel costs consisted of fuel purchased for field operations.
Net Loss
For the three months ended September 30, 2026, we incurred a net loss of $13,642,077 compared to a net loss of $2,895,585 for the three months ended September 30, 2025. The increase of $10,746,492 in net loss was primarily due to exploration and evaluation expenses of $6,304,794, which we did not incur in the prior-year period, an increase in professional fees of $3,518,588, principally marketing expenses, a $895,107 change from a gain to a loss on the change in fair value of warrant liabilities, an increase in general and administrative expenses of $599,764, an increase in other expense, net, of $465,072, which includes the $306,304 expense recognized as part of the Meteora forward purchase agreement, and an increase in research and development expenses of $136,216. These increases were partially offset by a $1,173,049 decrease in interest expense, because the prior-year period included interest related to the settlement of the Austria Capital convertible note.

Results of Operations for the Nine Months Ended September 30, 2026 Compared to the Nine Months Ended September 30, 2025
Revenues
The Company had no revenue for the nine months ended September 30, 2026 and 2025.
Operating Expenses
Our operating expenses for the nine months ended September 30, 2026 were approximately $27.4 million compared to approximately $5.3 million for the nine months ended September 30, 2025, an increase of approximately $22.1 million, or 414%. The increase was primarily attributable to higher professional fees, principally marketing and investor relations expenses; exploration and evaluation expenses related to our 2026 field program, which we did not incur in the prior-year period; higher general and administrative expenses, including share-based compensation; and higher research and development expenses.
34

Table of Contents
Professional fees increased by approximately $8.8 million, or 370%, to approximately $11.2 million for the nine months ended September 30, 2026 from approximately $2.4 million for the nine months ended September 30, 2025. The increase was primarily attributable to:
•approximately $7.6 million of marketing, investor awareness and investor relations expenses, which we did not incur in the prior-year period;
•approximately $1.0 million of additional legal, accounting, consulting and advisory costs associated with public company reporting requirements, regulatory compliance matters and corporate governance activities; and
•approximately $0.2 million related to technical, geological, engineering and other professional services incurred following the acquisition of Greenland Mines Corp. and in support of the Company’s mining operations and exploration activities.
General and administrative expenses increased by approximately $6.0 million, or 273%, to approximately $8.3 million for the nine months ended September 30, 2026 from approximately $2.2 million for the nine months ended September 30, 2025. The increase was primarily attributable to:
•approximately $4.3 million of higher share-based compensation expense associated with equity awards granted to employees, directors, officers and consultants; and
•approximately $1.7 million of additional payroll and personnel-related costs, insurance, site operations and other corporate and public company costs incurred following the Greenland Mines acquisition.
In addition, during the nine months ended September 30, 2026, the Company recognized transaction-related compensation expense, in cash and shares, for success-based payments to certain officers, directors and consultants that were contingent on the completion of the Greenland Mines merger in March 2026. These costs were expensed as incurred within general and administrative expenses.
Research and development expenses increased by approximately $383,893, or 51%, to $1,131,328 for the nine months ended September 30, 2026 from $747,435 for the nine months ended September 30, 2025. The increase was primarily attributable to scientific and clinical development activities, including engagements with third-party research institutions and consultants supporting the Company’s biotechnology programs.
The research and development expenses by program are as follows:
ProgramNine Months Ended
September 30, 2026
Nine Months Ended
September 30, 2025
KLTO-101 and KLTO-202$686,125 $747,435 
Klotho Clock256,236 - 
New Development121,750 - 
Other67,217 - 
Total$1,131,328 $747,435 
The Company expects research and development expenses to remain modest relative to the total operating expenses and to decline if the planned contribution of our biotechnology-related assets is completed (see Note 13), as the related programs would transfer to the counterparty.
Exploration and evaluation expenses were approximately $6,865,824 for the nine months ended September 30, 2026 compared to $0 for the nine months ended September 30, 2025. We had no mineral exploration operations before our March 2026 acquisition of Greenland Mines Corp. The expenses related principally to the Skaergaard Project, including our 2026 field program, which we completed on October 1, 2026, and, from September 1, 2026, the Sarfartoq Project. Of the total, $6,785,583 related to the Skaergaard Project and $80,241 to the Sarfartoq Project. They consisted primarily of vessel and aircraft charters, contracted drilling services, professional and technical services, and camp and logistics support, together with freight, fuel, equipment rental and sample analysis.

35

Table of Contents
The exploration and evaluation expenses by category were as follows:
CategoryNine Months Ended
September 30, 2026
Nine Months Ended
September 30, 2025
Drilling Costs and Supplies$1,887,097 $- 
Camp and Logistics988,309 - 
Assay and Sample Analysis22,253 - 
Equipment Rental - Mining129,539 - 
Professional and Technical Services1,501,889 - 
Freight and Shipping194,712 - 
Charter Expense1,998,614 - 
Fuel143,411 - 
Total Exploration and Evaluation Expense$6,865,824 $- 
Drilling costs and supplies consisted primarily of contracted diamond drilling services for the 2026 field program, together with core storage, explosives and geological supplies. Camp and logistics costs consisted primarily of helicopter support and crew travel, together with camp supplies and field communications equipment. Assay and sample analysis costs consisted of certified reference materials, blanks and sample packaging used in quality assurance, as laboratory assay results from the 2026 program were pending when the program was completed. Equipment rental costs related to drilling and blasting equipment, with operators, and geophysical survey equipment. Professional and technical services consisted of contract geologists and field personnel, drill planning and geotechnical support, environmental baseline studies and geophysical field services. Charter expense consisted of vessel and aircraft charters, including voyage costs. Freight and shipping costs consisted of export clearance and transport of equipment and samples. Fuel costs consisted of fuel purchased for field operations.
Total other expense was approximately $3.8 million for the nine months ended September 30, 2026 compared to approximately $3.4 million for the nine months ended September 30, 2025, an increase in net expense of approximately $326,571 or 9%. The 2026 amount consists of impairment expense of $2,045,253 on certain biotech licenses (see Note 5), a $1,314,780 loss from the change in fair value of warrant liabilities, other expense of $395,957 (including $306,304 recognized as part of the Meteora forward purchase agreement) and interest expense of $11,453. The 2025 amount consisted of $3,491,961 of interest expense on the Company’s convertible notes and related settlements and a $28,514 loss from the change in fair value of warrant liabilities, partially offset by other income of $79,603. The increase was primarily attributable to a a $2.0 million impairment charge on certain biotech licenses recognized in the nine months ended September 30, 2026, a $1.3 million higher loss from the change in fair value of warrant liabilities, and other expense compared to other income in the prior-year period, almost entirely offset by a decrease in interest expense of approximately $3.5 million, because the prior-year period included interest on the Company’s convertible notes and related settlements.

Net Loss
For the nine months ended September 30, 2026, we incurred a net loss of $31.2 million compared to a net loss of $8.8 million for the nine months ended September 30, 2025. The increase was primarily attributable to increases in professional fees, general and administrative costs, exploration and evaluation expenses, impairment expense and the loss from the change in fair value of warrant liabilities, partially offset by lower interest expense.
36

Table of Contents
Liquidity and Capital Resources
For the Nine Months Ended
September 30,
20262025
Net cash used in operating activities$(22,230,519)$(4,610,390)
Net cash used in investing activities(20,923,643)- 
Net cash provided by financing activities93,370,984 11,894,683 
Net increase in cash and cash equivalents$50,216,822 $7,284,293 
Cash, beginning of year7,176,615 63,741 
Cash, end of year$57,393,437 $7,348,034 
Operating Activities
Net cash used in operating activities for the nine months ended September 30, 2026 was $22,230,519, compared to $4,610,390 for the nine months ended September 30, 2025, an increase of $17,620,129. The increase reflects operating expenses of $27,416,897, of which $14,464,180 relates to our expansion, consisting of exploration and evaluation expenditures of $6,865,824 (primarily the Skaergaard Project) and marketing, investor awareness and investor relations expenses of $7,598,356, all of which were settled in cash. The remaining $12,952,717 relates to continued operations, consisting of general and administrative expenses of $8,258,865, other professional fees of $3,562,524 and research and development expenses of $1,131,328. The increase was partially offset by non-cash charges of $9,791,473, principally share-based compensation of $6,125,856, a generic drug license impairment of $2,045,253, a change in fair value of warrant liabilities of $1,314,780 and $306,304 of expense as part of the Meteora forward purchase agreement, and was increased by a net use of cash of $837,652 from changes in operating assets and liabilities, mainly prepaid expenses of $1,631,990.

Investing Activities
Net cash used in investing activities for the nine months ended September 30, 2026 was $20,923,643, compared to $0 for the nine months ended September 30, 2025. Cash used in investing activities during 2026 consisted of $19,995,724 for our acquisition of NNSR Holdings Inc., net of cash acquired and including $120,482 of capitalized acquisition costs, $451,445 of purchases of property and equipment and $476,474 for our acquisition of mineral rights and exploratory licenses. Our June 2026 share exchange with AnorTech Inc.($3,682,800) and the common stock and Series R Convertible Preferred Stock issued as part of the Sarfartoq consideration ($5,444,045) were non-cash transactions, settled through the issuance of our common stock, and accordingly is excluded from investing activities and presented as a supplemental non-cash disclosure.

Financing Activities
Net cash provided by financing activities for the nine months ended September 30, 2026 was $93,370,984, consisting primarily of approximately $7.75 million of gross proceeds from our March 2026 private placement, $3.75 million of gross proceeds from our June 2026 private placement, approximately $3.93 million of net proceeds from sales under our at-the-market sales agreement, $3.71 million from the exercise of warrants, approximately $18.49 million of net proceeds from our August 2026 registered direct offering, approximately $55.56 million of proceeds from our two September 2026 registered direct offerings ($38.40 million and $17.16 million), and $412,329 from the settlement of shares under the forward purchase agreement, partially offset by $220,418 of principal repaid on notes payable to related parties. Net cash provided by financing activities for the nine months ended September 30, 2025 was $11,894,683, which consisted of $11,394,218 of net proceeds from sales of common stock and warrants, $2,150,000 of net proceeds from convertible promissory notes, $500,000 from stock subscriptions, $500,000 from the sale of Preferred B shares, $140,572 from the settlement of shares under the forward purchase agreement and $5,300 of proceeds from sales under our at-the-market sales agreement, partially offset by $2,730,182 of payments on notes payable, $40,225 of payments on financed director and officer insurance, and $25,000 of deferred financing costs.

Liquidity, Capital Resources and Going Concern
As of September 30, 2026, we had cash and cash equivalents of $57.4 million and net working capital of $58.5 million.
37

Table of Contents
We have incurred, and expect to continue to incur, significant professional costs to remain a publicly traded company, and we expect to incur significant costs in connection with our exploration and evaluation activities at the Skaergaard Project and the Sarfartoq Project.
On September 1, 2026, we completed our acquisition of NNSR Holdings Inc., the sole stockholder of Neo North Star Resources, Inc., which holds the Sarfartoq rare earth exploration project in Greenland. At closing, we paid $19.9 million in cash and issued 1,040,676 shares of common stock and 359,324 shares of Series R Convertible Preferred Stock. We accounted for the transaction as an asset acquisition under ASC 805-50 because substantially all of the fair value of the gross assets acquired is concentrated in the Sarfartoq exploration license, and we recognized no goodwill. We measured the equity consideration at its fair value on the acquisition date of $5.4 million, based on our $4.65 closing share price on September 1, 2026 and discounts for lack of marketability, and, for the Series R, the timing of the stockholder approval required before conversion. The consideration transferred was therefore $25.3 million, and we also capitalized $0.1 million of transaction costs. We funded the cash portion with cash on hand, including proceeds from our August 2026 registered direct offering. See Note 3.

Effective July 4, 2026, we terminated our At-the-Market Sales Agreement with A.G.P./Alliance Global Partners, under which we had sold 197,802 shares for gross proceeds of approximately $2.66 million during the six months ended June 30, 2026. In August 2026, we resumed sales through A.G.P. under a sales agreement in August, 2026 and sold 143,505 shares for gross proceeds of $1,388,827. On September 23, 2026, our Board of Directors approved the termination of that sales agreement, and no further shares will be sold. As a result, the at-the-market program is no longer available to us as a source of liquidity. See Note 10.

Our September 2026 registered direct offerings substantially utilized the remaining capacity under our existing shelf registration statement, and we have terminated our at-the-market program, so our ability to raise additional capital through registered offerings under that shelf is limited. In our press releases of September 24 and 29, 2026, we stated that the capital raised provides the capital required to execute our planned exploration and development programs and achieve our 2027 milestones.

The accompanying condensed consolidated financial statements have been prepared on a going concern basis. We have incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2026, we had cash and cash equivalents of approximately $57.4 million and an accumulated deficit of approximately $52.3 million. In accordance with ASC 205-40, management evaluated whether conditions or events, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. Based on our cash balance and our forecast of cash spend through September 30, 2027, which assumes no additional financing, management concluded that our cash and cash equivalents are sufficient to fund our planned operations for at least twelve months from the date these financial statements are issued and that substantial doubt does not exist. We expect to continue to incur operating losses and expect to need additional capital over the longer term to fund the exploration, evaluation and development of our mineral properties.

Nasdaq Continued Listing, Minimum Bid Price
Our common stock is listed on the Nasdaq Capital Market under the symbol “GRML.” On September 19, 2025, we received a notification letter from Nasdaq indicating that we were not in compliance with the $1.00 minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2), because our common stock had closed below $1.00 per share for 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were initially provided 180 calendar days, or until March 18, 2026, to regain compliance. On March 19, 2026, Nasdaq granted us a second 180-calendar-day compliance period, through September 14, 2026. To regain compliance, the closing bid price of our common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period.
At a special meeting held on June 18, 2026, our stockholders approved a proposal authorizing our Board of Directors to effect one or more reverse stock splits of our outstanding common stock at a ratio of between 1-for-2 and 1-for-50, at the Board’s discretion at any time on or before March 31, 2027, provided that the aggregate ratio of all such reverse stock splits does not exceed 1-for-60. On August 24, 2026, we effected a 1-for-50 reverse stock split of our common stock in an effort to satisfy the minimum bid price requirement. The reverse stock split reduced our outstanding common stock from 158,850,637 shares to 3,177,094 shares before the fractional share round-up, did not change our authorized shares or the par value of our common stock, and has been applied retroactively to all periods presented in this Quarterly Report. We regained compliance with the minimum bid price requirement on September 2, 2026, after the closing bid price of our common stock was at least $1.00 per share for ten consecutive business days, and Nasdaq notified us of that on September 2, 2026.

There can be no assurance that we will maintain compliance with the minimum bid price requirement or Nasdaq’s other continued listing requirements. If we do not, our common stock could be subject to delisting from Nasdaq, subject to our right to appeal to a Nasdaq Hearings Panel. A delisting would likely reduce the liquidity and market price of our common
38

Table of Contents
stock and could further impair our ability to raise capital, particularly following the termination of our at-the-market sales agreement.

We have no obligations, assets, or liabilities that would be considered off-balance sheet arrangements as of September 30, 2026. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. Preparing these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and of expenses during the reporting period. We base our estimates on historical experience and on other assumptions we believe are reasonable under the circumstances, and actual results could differ materially from those estimates.
Our significant accounting policies are described in Note 2 to our condensed consolidated financial statements and in our Annual Report on Form 10-K for the year ended December 31, 2025. As a result of the transactions completed during the nine months ended September 30, 2026, the following estimates involve a significant level of estimation uncertainty and have had, or are reasonably likely to have, a material impact on our financial condition and results of operations.
Fair value of acquired mineral exploration rights and equity consideration

In connection with our March 2026 acquisition of Greenland Mines Corp., which we accounted for as an asset acquisition under ASC 805-50, we measured the consideration transferred, principally 47,940 shares of Series C Preferred Stock, at a fair value of $47.9 million, and allocated total acquisition costs of $48.4 million to the acquired mineral exploration rights and exploration licenses. Fair value of the Series C Preferred Stock was determined using a combination of discounted cash flow and market-based methods, with significant unobservable inputs including projected future cash flows based on expected mineral production, commodity price assumptions, and discount rates. These inputs are classified within Level 3 of the fair value hierarchy, and different assumptions could have produced a materially different carrying value.

In connection with our September 1, 2026 acquisition of NNSR Holdings Inc., the sole stockholder of Neo North Star Resources, Inc., which we also accounted for as an asset acquisition under ASC 805-50, we measured the consideration transferred, consisting of $19.9 million of cash, 1,040,676 shares of common stock and 359,324 shares of Series R Convertible Preferred Stock, at $25.3 million, and allocated total acquisition costs of $25.4 million, including $0.1 million of transaction costs, to the acquired mineral rights and exploration license. We measured the common stock at the $4.65 closing price on the acquisition date less a 14.0% discount for lack of marketability, or $4.2 million, and the Series R Convertible Preferred Stock at $1.3 million. The discounts for lack of marketability are significant unobservable inputs, and different assumptions would have changed the consideration transferred and the carrying value of the mineral property.

Impairment of long-lived and intangible assets
We assess our long-lived and intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. During the nine months ended September 30, 2026, we recognized impairment expense of $2,045,253 related to certain biotech licenses, all of which was recognized in the three months ended March 31, 2026. Our mineral exploration rights and exploration licenses of $73.9 million are early-stage exploration assets that are not yet ready for their intended use and are not amortized. Their recoverability depends on future exploration success, the availability of financing, regulatory approvals, and the establishment of economically recoverable reserves, none of which is assured, and a change in these judgments could result in a material impairment charge.

Fair value of warrant liabilities
We measure our warrant liabilities at fair value on a recurring basis. The 530,000 legacy private warrants outstanding at September 30, 2026 are measured at the quoted price of our publicly traded warrants (Level 2). Until their exercise on September 22, 2026, the warrants issued in our March 2026 private placement were measured using a Black-Scholes option pricing model with significant unobservable (Level 3) inputs, including expected volatility and expected life, and on the exercise date at their intrinsic value. Changes in our share price and in the quoted warrant price can produce material changes in fair value that are recognized in earnings.

39

Table of Contents
Investment in equity securities
Our investment in AnorTech Inc. does not have a readily determinable fair value, and we have elected the measurement alternative under ASC 321, carrying the investment at cost less impairment, adjusted for observable price changes. Determining whether an observable price change has occurred in an orderly transaction, and whether the investment is impaired, requires significant judgment, particularly given the contractual lock-up on the shares and the limited trading in AnorTech’s securities.
Going concern
Our evaluation of whether substantial doubt exists about our ability to continue as a going concern requires significant judgment regarding forecasted cash flows and the availability of future financing. See “Liquidity, Capital Resources and Going Concern.”

Emerging Growth Company Status
We are an “emerging growth company”, as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company, we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging growth company.
We will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of our initial public offering; (ii) the first fiscal year after our annual gross revenues are $1.235 billion or more; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If, as a result of our decision to reduce future disclosure, investors find our common stock less attractive, there may be a less active trading market for our common stock and the price of our common stock may be more volatile.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to make disclosures under this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of September 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2026, our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified by Securities and Exchange Commission (“SEC”) rules and forms and (b) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure.
Management has identified material weaknesses relating to inadequate accounting resources, a lack of segregation of duties, and the need for a stronger internal control environment. Management believes these material weaknesses are attributable to the small size of our accounting staff. The small size of our outsourced accounting staff may prevent us from implementing adequate controls in the future due to the cost and benefit of such remediation.
To mitigate our currently limited resources and limited number of employees, we rely heavily on direct management oversight of transactions, together with the use of external legal and accounting professionals. As we grow, we expect to
40

Table of Contents
increase our number of employees, which will enable us to implement adequate segregation of duties within our internal control framework.
These material weaknesses could result in a misstatement of account balances such that there is a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. In light of these material weaknesses, we have undertaken the following remediation activities:
•Conducted a risk assessment to identify gaps in internal controls over financial reporting
•Enhanced existing controls and implemented new controls as needed to address control gaps
•Tested key controls to verify operating effectiveness
•Documented narratives detailing enhanced processes and controls
These remediation efforts are ongoing, and the material weaknesses described above had not been fully remediated as of September 30, 2026. Notwithstanding the material weaknesses, management believes that our condensed consolidated financial statements for the three and nine months ended September 30, 2026 are fairly stated, in all material respects, in accordance with U.S. GAAP.
Changes in Internal Control Over Financial Reporting
Except for the remediation activities described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
41

Table of Contents
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
As a smaller reporting company, we are not required to make disclosures under this Item.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
All information required by Item 701 of Regulation S-K has previously been included in a Current Report on Form 8-K.
After the end of the quarter, as of October 5, 2026, our Board of Directors authorized a share repurchase program for up to $20 million of our common stock, which we announced on October 6, 2026. See Note 13.

Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Insider Trading Arrangements and Policies
During the quarter ended September 30, 2026, none of the Company’s directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
42

Table of Contents
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.
Exhibit No.Description
19.1***
Klotho Neurosciences, Inc. Insider Trading Policy (incorporated by reference to Exhibit 19.1 filed by Klotho Neurosciences, Inc.’s on Form 10-Q filed with the SEC on November 19, 2024).
23.1*
Consent of SLR Environmental Consulting (Ireland) Ltd, Qualified Person, regarding the S-K 1300 Technical Report Summary for the Skaergaard Project
23.2*
Consent of Geosim Services Inc. (Canada), Qualified Person, regarding the S-K 1300 Technical Report Summary for the Sarfartoq Project
23.3*
Consent of Tetra Tech Canada Inc., Qualified Person, regarding the S-K 1300 Technical Report Summary for the Sarfartoq Project
31.1*
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification of Principal Accounting and Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**
Certification of Principal Accounting and Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
96.1*
S-K 1300 Technical Report Summary for Skaergaard Project, part of Greenland Mines Ltd. as of July 3, 2026
96.2*
S-K 1300 Technical Report Summary for Sarfartoq Project, part of Greenland Mines Ltd. as of July 31, 2026
97.1***
Clawback policy (incorporated by reference to Exhibit 97.1 filed by Redwoods on Form 10-K filed by the Registrant on April 17, 2024).
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)
*Filed herewith.
**Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
***Filed previously.
43

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
GREENLAND MINES LTD
Date: November 16, 2026
By:/s/ Joseph A. Sinkule
Name:Joseph A. Sinkule
Title:Chief Executive Officer
(Principal Executive Officer)
Date: November 16, 2026
By:/s/ Jeffrey LeBlanc
Name: Jeffrey LeBlanc
Title:
Chief Financial Officer
(Principal Accounting Officer)
44

Keep reading